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The inclusion of biologically relevant ligands in coordination compounds of 
ruthenium is geared towards improving the biodistribution patterns of these metal 
complexes.  In this research study, we investigate the coordination behaviours of N, 
X-donor (X = O, N or S) heterocyclic ligands incorporating various biologically 
active components (viz. benz(imidazole/othiazole/oxazole), chromone, 
tetrahydropyran, pyrrole or lumazine) towards ruthenium in its oxidation state of 
+II. The resultant ruthenium compounds were characterized via various 
spectroscopic techniques and structural elucidation was confirmed using single 
crystal X-ray diffraction analysis. The structural elucidation was complemented with 
electro-analytical, radical scavenging and DFT studies. 
 
Novel ruthenium(II) and –(III) complexes of Schiff bases containing benzimidazole 
(bz), benzothiazole (bs) or benzoxazole (bo) moieties were formulated and 
characterized in chapter 3. The diamagnetic ruthenium complex, cis-
[RuIICl2(bzpy)(PPh3)2] (1) was formed from the 1:1 molar reaction between N-
((pyridine-2-yl)methylene)-1H-benzimidazole (bzpy) and metal precursor, trans-
[RuCl2(PPh3)2]. The same metal precursor, when reacted with the benzimidazole-
derived Schiff bases [N-(2-hydroxybenzylidene)-benzothiazole (Hbsp) and N-(2-
hydroxybenzylidene)-benzimidazole (Hbzp)], afforded the paramagnetic ruthenium 
(III) complexes [RuCl(bsp)2(PPh3)] (2) and  trans-[RuCl(bzp)(PPh3)2] (3), respectively. 
Trans-[RuCl2(PPh3)2] also gave a diamagnetic ruthenium(II) complex, cis-
[RuIICl2(bxth)(PPh3)2] (4) when reacted with N-((thiophene-2-yl)methylene)-
benzoxazole (bxth). These metal complexes were characterized via IR, mass and UV-
Vis spectroscopy, elemental analysis, single crystal XRD analysis (for 1-3) as well as 
conductivity measurements. Their redox properties were probed by voltammetry 
and accompanying UV-Vis spectroelectrochemistry (for 1-3) experiments. Structural 




NMR spectroscopy. The presence of the paramagnetic metal centres of 2 and 3 were 
confirmed by X-band ESR spectroscopy.  
 
Chapter 4 describes the formation of novel ruthenium(II), -(III) and –(IV) compounds 
containing benzoxazole-amide, benzimidazole-amine and chromone- derived Schiff 
base ligands. A paramagnetic ruthenium(IV) complex, [RuCl(pho)(bzca)(PPh3)] (1) 
(pho = 2-aminophenolate; bzca = 2-carboxylate-1H-benzimidazole) was isolated 
from the reaction of the ruthenium(II) precursor, trans-[RuCl2(PPh3)3] and 2-((1H-
benzimidazole)methylamino)phenol (Hbzap). The 1:1 molar reaction between the 
same metal precursor and N-(benzoxazole)-2-hydroxybenzamide (H2bhb) led to the 
formation of cis-Cl, trans-P-[RuIII(Hbhb)Cl2(PPh3)2] (2). The dinuclear ruthenium 
compounds, (μ-Htba,Cl)2[RuIICl(PPh3)]2 (3) (Htba = N-(thiophene)methyl-
benzoxazole-2-amine) and (µ-Cl)2[RuIIICl(Hchpr)(PPh3)]2 (4) (H2chpr = 2-amino-3-
((tetrahydro-2H-pyran-4-ylimino)methyl)-4H-chromen-4-one) were formed from the 
equimolar ratio coordination reactions between trans-[RuCl2(PPh3)3] and the 
respective free-ligands, Htba and  H2chpr. These metal complexes were 
characterized using IR-, NMR- and UV-Vis spectroscopy; molar conductivity 
measurements and structural elucidation was confirmed by single crystal X-ray 
analysis. The X-ray studies revealed that all the metallic compounds exhibited 
octahedral geometries and that the Hbzap free ligand have undergone a unique 
molecular transformation to afford the pho and bzca bidentate chelators in 1.  The 
electrochemical properties of the respective metal complexes were investigated by 
voltammetric analysis. The cyclic voltammograms (CVs) of 1, 2, 3 and 5 showed one 
redox couple each while within the CV of the dinuclear compound 4, two redox 
couples are observed. The ligands and their metal complexes were also subjected to 
DPPH radical scavenging studies. The IC50 values showed that all the metallic 
compounds have higher radical scavenging activities than their corresponding free-




[RuIICl2(Hbzpy)(PPh3)2] (5) was also formed using N-((pyridine-2-yl)methyl)-1H-
benzimidazole (Hbzpy) ligand and  aforementioned metal precursor.  
Chapter 5 focuses on the coordination modes of di- and triimine chelators towards 
the ruthenium(II) and -(III) centres. The coordination reactions of 2,6-bis-((4-
tetrahydropyranimino)methyl)pyridine (thppy), N1,N2-bis((3-chromone)methylene)-
benzene-1,2-diamine (chb) and tris-((1H-pyrrol-2-ylmethylene)ethane)amine 
(H3pym) with trans-[RuIICl2(PPh3)3] afforded the diamagnetic ruthenium(II) 
complex, cis-[RuCl2(thppy)(PPh3)] (1), the paramagnetic compounds (µ-chb)[mer-
RuCl3(PPh3)]2 (2) and [Ru(pym)] (3), respectively. The synthesized metal complexes 
were characterized via IR-, NMR- and UV-Vis spectroscopy; molar conductivity 
measurements as well as structural elucidation which were confirmed by single 
crystal X-ray diffraction. The redox properties of the metal complexes were probed 
via cyclic– and squarewave voltammetry. The radical scavenging capabilities of the 
metallic compounds towards the NO and DPPH radicals were investigated. 
 
In chapter 6, new ruthenium(II) and -(III) complexes encompassing multidentate 
ligands derived from 6-acetyl-1,3,7-trimethyllumazine (almz) are described. The 1:1 
molar coordination reactions of trans-[RuCl2(PPh3)3] with N-1-[1,3,7-
trimethyllumazine]benzohydride (bzlmz) and 6-(N-methyloxime)-1,3,7-
trimethyllumazine (ohlmz)  formed a diamagnetic ruthenium(II) complex, cis-
[RuCl2(bzlmz)(PPh3)] (1) and a paramagnetic complex, cis-[RuIIICl2(olmz)(PPh3)] (2) 
[olmz = 6-(N-hydroxy-N‘-methylamino)-1,3,7-trimethyllumazine], respectively. 
These ruthenium complexes were characterized via IR-, NMR-, UV-Vis and TOF-MS 
spectroscopy, elemental analysis, melting point and molar conductivity 
measurements. Structural elucidation of the metal complexes was confirmed using 
single crystal X-ray analysis. The redox properties of the metal complexes were 
investigated via cyclic voltammetry. ESR spectroscopy confirmed the presence of 
paramagnetic metal centres of 2 . The radical scavenging activities of the metal 




calculations at the DFT level provided insight in the interpretation of the 
experimental spectra of 1. 
 
Keywords: Ruthenium; Schiff base; Benz(imidazole/othiazole/oxazole); Lumazine; 
Amine; Amide; Heterocyclic; Crystal structure; Redox properties; Radical 
























The experimental work described in this thesis was carried out in the School of 
Chemistry and Physics at the University of KwaZulu-Natal, Pietermaritzburg, from 
February 2012 to December 2015, under the supervision of Dr. Irvin Noel Booysen.  
 
These studies represent original work by the author and have not otherwise been 
submitted in any form for any degree or diploma to any tertiary institution. Where 
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1.1 General Background 
Ruthenium is a group 8 transition metal positioned in the second row of the periodic 
table. It belongs to a collection of metals classified as the Platinum Group Metals 
(PGMs) which also includes Osmium, Rhodium, Palladium, Iridium and Platinum. All 
these metals have closely associated physical and chemical properties. These metals 
typically occur together in the same mineral deposits [1]. Ruthenium is one of the rarest 
elements in the earth’s crust being the 74th most abundant element on earth [2, 3]. 
Naturally occurring ruthenium is made up of seven stable isotopes while several 
radioactive isotopes have been discovered with atomic weights ranging from 87 to 120. 
Among these radioisotopes, 106Ru, 103Ru and 97Ru are the most stable with half-life of 
373.59 days, 39.2 days and 2.9 days, respectively [4, 5]. 
 
This transition metal possesses an electronic configuration of [Kr]4d75s1 which confers 
its unique redox properties through its capability to exhibit a wide range of oxidation 
states. In fact, the variable valency is emphasized by the oxidation states of -II as in 
Ru(CO)42- and +VIII as in RuO4 which corresponds to d0 and d10 electronic 
configurations, respectively [6]. The +II, +III and +IV oxidation states are the most 
common, of which the +III state is substitutionally more inert, a feature which has 
proved useful for a number of single-electron transfer studies [7, 8]. 
 
Ruthenium complexes exhibiting octahedral coordination geometry allows for the 
inclusion of specific ligands in a controlled manner to refine the photophysical, 






ruthenium is dictated by its affinity for nitrogen donor ligands such as in the 
[Ru(bipy)]2+(bipy = bipyridine) core [10]. Furthermore, ruthenium complexes have 
received a lot of interest and are now studied extensively for their wide range of 
biological activities (e.g. anticancer, antimicrobial and antioxidant) [11]. This upsurge in 
research is attributed to the discovery of imidazolium-trans-
imidazoledimethylsulfoxide-tetrachlororuthenate (III) (NAMI-A) and indazolium-trans-
[tetrachloro-bis (1H-indazole) ruthenate(III)] (KP-1019) which have both entered clinical 
trials as ruthenium anticancer drugs [12, 13]. 
 
1.2     Aim and Motivation 
A current design strategy for discovering the next generation of ruthenium-based 
metallodrugs involves the incorporation of biologically relevant moieties into their 
chelators [14]. Hypothetically, these biologically active moieties should improve the 
biodistribution patterns of formulated ruthenium metallodrugs and possibly increase 
its solubility into the blood stream. In addition, the inclusion of a biologically active 
moiety can induced biocompatibility of the formulated ruthenium 
metallopharmaceuticals and also avoids the development of drug-resistant diseases 
[15]. Moreover, meticulous ligand design can ensure optimal DNA binding capability 
coupled with possibilities of ionic or direct covalent bonding interactions by the 
ruthenium metal centre to the DNA double helix [16]. Furthermore, the capability of 
ruthenium to imitate iron in binding to transferrin plays a huge part in the general low 
toxicity of ruthenium based metallodrugs [17]. Thus, within this study, our aim is to 
design ruthenium with multidentate N, X-donor (X = O, N, S) chelators incorporating 
various biologically relevant moieties. More specifically, biologically active moieties 
including benzimidazole (bz), benzothiazole (bs), benzoxazole (bo), chromone (chr), 
tetrahydropyran (thp), pyrrole (pyr) and lumazine (lmz) were considered within this 
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Figure 1.1:  Structures of the biologically active moieties considered within the study. 
 
Compounds containing benz(imidazole/othiazole/oxazole) moieties are building 
blocks for many compounds which have displayed different pharmacological activities 
[18, 19]. Like in the case of the bis-benzoxazole natural product analogue, [2,4'-
bibenzoxazole]-4-carboxylicacid, 2'-(2-hydroxyphenyl) methyl ester (UK-1) which has 
shown potent anticancer activities against a wide spectrum of cell lines such as 
leukaemia and lymphoma [20], refer to Figure 1.2.  Indicative to the aforementioned N-
donor heterocyclic compounds, pyrroles and their derivatives exhibit a wide range of 






fact that pyrroles are found in many natural products such as porphyrins, chlorins, 
chlorophylls and corrins [25, 26]. For example, Astorvastatin, (Figure 1.3) contains a 
synthetic derivative of pyrrole: A drug used primarily for lowering blood cholesterol 


























Figure 1.3: Structure of Atorvastatin, a drug used for the treatment of cardiovascular diseases. 
 
Our choice in the consideration of chromone moiety rested on its biological relevance as 
a secondary metabolite and that transition metal complexes with Schiff base chelates 
bearing the chromone moiety are optimal DNA interchelators [28]. Our research study 
advanced further to the tetrahydropyran moiety as it has the same structural core of the 
carbohydrates. Synthetically, the tetrahydropyran moiety forms an integral constituent 
of the architectural setup of Phorboxazole, (Figure 1.4) isolated from an Indian Ocean 











Lastly, lumazine acts as a substrate for the riboflavin synthase complex, an enzyme 
complex that catalyses the conversion of two molecules of lumazine into Riboflavin 
(vitamin B2) [32, 33], refer to Figure 1.5. Furthermore, one of the annealed ring systems 
of lumazine is a uracil which in turn is a constituent of well-established 
chemotherapeutic drugs, uramustine [Figure 1.6 (a)] and 5-fluoro-uracil [Figure 1.6(b)] 
[34, 35]. In fact, Booysen et al. have already demonstrated coordination susceptibility of 
Schiff bases derived from 5,6-diamino-1,3-dimethyluracil towards ruthenium in its 
oxidation state +II [36]. Therefore, the aforementioned research study allowed impetus 
to investigate the coordination reactions of trans-[RuCl2(PPh3)3] and multidentate 
































(a)                                                          (b)  
Figure 1.6: Structure of (a) uramustine and (b) 5-fluoro-uracil. 
 
The incorporation of biological active moieties (BAM) into multidentate chelators 
readily occurs through the formation of Schiff bases. The ruthenium centre generally 
has high coordination affinity to imino nitrogens and this class of ligands stabilizes 
ruthenium both in the low and high oxidation states. Another advantage includes the 
fact that numerous Schiff bases derived from biological active moieties has already been 
formed and subsequently coordinated to various transition metals. In fact, some 
transition metal complexes showed increased biological activities with regard to their 
free Schiff base ligands derived from BAMs [37]. However, some of the formulated 
Schiff bases within our research study have shown to be characteristically 
hydrolytically unstable and this phenomenon was combated by utilizing more robust 









1.3  Schiff base metal complexes 
Transition metal complexes containing Schiff base ligands possess the capability to 
stabilize different metals in various oxidation states [39]. This capability originates from 
the fact that numerous metal centres have affinity for the imino nitrogen and the 
coordination susceptibility for other metal ions can be tailored through the 
manipulation of other donor atoms which can be readily achieved by functionalization 
and derivatization of Schiff bases. In addition, the combination of hard and soft donor 
atoms (viz. nitrogen and oxygen) in Schiff bases incorporating 
benz(imidazole/othiazole) moieties have shown to be successful chelators to the acidic 
[VIVO]2+ and [VVO2]+ cores, see Figure 1.7 [40]. Furthermore, multidentate Schiff bases 
are known to stabilize transition metals through chelation and even encapsulation (i.e. 
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Figure 1.7: A trigonal bipyrimidal dioxovanadium(V) complex bearing a monoanionic 







More interestingly, the conformational effects imparted by the diimine chelators on d6 
metal centres have resulted in metal complexes with peculiar electronic properties. For 
example, diimine ruthenium (II) complexes typically show intense intraligand (π*→π) 
relaxations accompanied by more red-shifted dπ(Ru) → π* MLCT relaxation with more 
longer lifetimes, ideally suited for applications in photocatalysis, photosensitization and 
photoelectrochemical sensing [42-44]. Also, altering the stereoelectronic properties of 
Schiff bases of d-block elements have induced significant influence on their redox and 
catalytic properties. More specifically, the series of paramagnetic ruthenium(III) 
complexes, trans-[Ru(H2O)2(Ln)2]Cl {n = OCH3, CH3, H, Cl or NO2} where L is 
monoanionic bidentate chelators derived from 2-hydroxy-naphthaldehyde and the 
corresponding derivatized anilines; showed optimal catalytic activity towards the 
oxidation of benzoin, see Figure 1.8 [45]. The variable turn-over frequencies suggested 
that the nature of the para-substituent had significant influence on the efficiency of the 
molecular transformation to benzil.  












Figure 1.8: The generic structure of the ruthenium (III) catalysts, trans-[Ru(H2O)2(Ln)2]Cl {n = 







Recently, researchers have also been showing interest in the nanofabrication of 
nanoconjugates of Schiff base metal complexes. For example, multi-walled carbon 
nanotubes (MWCNTs) covalently linked to a palladium(II) Schiff base metal complex 
afforded higher heterogeneous catalytic activity in comparison to when only the 
aforementioned Schiff base metal complex was used (see Figure 1.9) [46]. The rationale 
behind the use of carbon nanotubes is due to their high surface area and their network 
of sp2-hybridised carbon atoms rendering excellent conductive properties. Furthermore, 
they are also thermally stable which aids in stabilizing Schiff bases which are 










Figure 1.9: Nanoconjugates comprising of a Pd(II) Schiff base complex and a MWCNT.  
 
1.4 Development of ruthenium metallopharmaceuticals 
Following the discovery of the potent anticancer activity of Cisplatin, {cis-[PtCl2(NH3)2]} 
[Figure 1.10(a)] in the 1960s, there has been growing interest to design other platinum-
based metallo-drugs with fewer side effects [50]. Despite cisplatin being active against 






healthy cells leading to gastrointestinal tract degradation (viz. nausea, vomiting, 
diarrhoea and abdominal pain), hair loss, skin ailments, neuromuscular complications, 
renal tubular injury and ototoxicity [50, 51]. To combat these side-effects, second 
generation platinum anticancer drugs (e.g. carboplatin [Figure 1.10(b)] and oxaliplatin 
[Figure 1.10(c)]) have been synthesized and found to be more stable and less neurotoxic 
than cisplatin [52, 53]. However, regardless of the significant advances made in utilizing 
platinum-based drugs for cancer therapy, a new class of chemotherapeutic drugs are 
required that should target the different types of cancer cells specifically and ultimately 
lead to no or minimal side-effects as well as avoid the development of drug resistant 























Figure 1.10: Structures of (a) cisplatin (b) carboplatin and (c) oxaliplatin. 
 
Among the numerous metals considered for developing novel anticancer drugs, 
ruthenium share an essential attribute with platinum given by the fact that ruthenium 
(II) and -(III) complexes have substitution kinetics similar to platinum(II) complexes 






biological molecules including serum proteins like transferrin and albumin, is a 
property believed to contribute to the general low toxicity of ruthenium drugs [55, 56]. 
Furthermore, ruthenium exhibits optimal redox properties which have shown to be a 
significant contributing factor in the scavenging capabilities of free radicals associated 
with inducing cancer [57]. 
 
Consequently, numerous ruthenium based compounds in their oxidation states +II or 
+III have been isolated and their anti-tumour activities evaluated. Ruthenium red, 
[(NH3)5Ru-O-Ru(NH3)4-O-Ru(NH3)5]6+, happened to be the first ruthenium compound 
to be used for biomedical purposes including as an electron microscopy stain and a 
blocking agent for Ca2+ ions [58, 59]. The first reported anticancer activity of ruthenium 
compounds; fac-[RuCl3(NH3)3] and cis-[RuCl2(NH3)4]Cl were found toinduce 
filamentous growth of E. coli at concentrations comparable to those at which cisplatin 
generates similar effects. However, the main demerit of these metal complexes was their 
low solubility in physiological media [60, 61].  
 
Currently, trans-[RuIIICl4(DMSO)(Im)](ImH) {ImH = protonated imidazole} (NAMI-A) 
[Figure 1.11(a)] and trans-[RuIII(Ind)2Cl4][IndH] (Ind = protonated indazole) (KP-1019) 
[Figure 1.11(b)] are the first ruthenium-based drugs that have reached phase II clinical 
trials with both having similar structural features but surprisingly different 
biodistribution patterns. NAMI-A seems to minimize the metastatic potential of 
tumours, regardless of the absence of a notable reduction of the primary tumour growth 
[62]. Though NAMI-A can interchelate between the DNA base pairs, this doesn’t appear 
to be the origin of its mechanism of activity. It rather appears to act as an anti-
angiogenic and anti-invasive agent unlike KP1019 which has displayed direct cytotoxic 




































Figure 1.11: The leading candidates for the ruthenium chemotherapeutic drugs: (a) NAMI-A 
and (b) KP1019. 
 
Furthermore, a number of organometallic ruthenium (II) arenes containing 1, 3, 5- 
triaza-7-phosphaadamantane (PTA) ligands, known as RAPTAs (refer to Figure 1.12) 
have been discovered and these metal complexes have shown to exhibit diverse 
biological activities [66]. These potential chemotherapeutic drugs are potent because of 
their high selectivity towards tumour cells accompanied with minor systemic toxicity to 
healthy cells. Unlike classical DNA interchelators which don’t share a defined 
biodistribution pattern, this class of ruthenium compounds act as pro-drugs where they 
combine with proteins in a peculiar way and the resultant adduct is proposed to be the 
principal constituent under physiological conditions. Hence indicative to NAMI-A, 






developed in vivo antimetastatic activity [67]. Especially, RAPTA-T has been proven to 















Figure 1.12: Schematic representation of selected RAPTA-Ru(II)-arene analogues. 
 
1.5 General Chemistry of Ruthenium 
1.5.1 Ligand Substitution 
Low spin ruthenium (II) complexes are kinetically inert but ligand substitution can be 
boosted using metal precursors (e.g. cis-[RuCl2(bpy)2], trans-[RuCl2(PPh3)3] and (µ-
Cl)2[RuCl(p-cymene)]2)with labile co-ligands within the coordination environments of 
the ruthenium(II) metal precursors [69]. For example, the substitution reaction between 
the ruthenium(II) complex, [Ru(terpy)bipy(H2O)]2+ (terpy = 2, 2: 6’, 2”-terpyridine, bipy 
= 2, 2’-bipyridine) and biologically relevant sulphur donor nucleophile, thiourea is 
described in equation (1) [70]. 
 







Interestingly, the substitution kinetics of [Ru(terpy)(HPB)H2O](PF6)2 {HPB = 2-(2’-
hydroxyphenylbenzoxale} indicated that it is ligand substitution by pyridine which 
occur via an initial reduction of the [Ru(III)-H2O] complex to [Ru(II)-H2O] complex 
before the substitution of the aqua ligand by pyridine occurs [71]. 
 
1.5.2 Redox reactions 
Ruthenium compounds in its oxidation states of +II and +III are highly redox active and 
as a result, they are susceptible to ligand induced redox reactions. This can be seen in 
equation (2) whereby an organometallic ruthenium(III) complex,trans-P, cis-Cl-
[RuIII(pch)Cl2(PPh3)2] (pch = 4-((pyridine-2-ylimino)methylene)chromone) is formed 
from the diamagnetic metal precursor, [trans-[RuIICl2(PPh3)3] [72]. 
 
[RuIICl2(PPh3)3] + pch →[RuIII(pch)Cl2(PPh3)2] + PPh3                                                                       (2) 
 
A series of ruthenium(III) complexes have shown the tendency to be oxidized to RuIV or 
RuV species by various oxidants. An example is the reaction of trans-[RuIICl2(PPh3)3] 
with  H3hdp ligand (H3hdp = 5-(2-hydroxybenzylideneamino)-6-amino-1,3-
dimethyluracil). The hydrolysis of H3hdp occurred to form the ddd ligand (ddd = 5,6-
diamino-1,3-dimethyluracil) and the resulting ddd ligand induced oxidation of the 











Extensive studies have been carried out on disproportionation reactions of ruthenium 
complexes owing to the relevance of the products (as oxidants and reductants) in DNA-
oxidation studies and organometallic catalysis. In particular, ruthenium(III) complexes 
are known to disproportionate into Ru(II) and Ru(IV) species under basic conditions. 
Choi et al. reported the disproportionation of [RuIII(NH3)5(dGuo)] {d(Guo) =  2’-
deoxyguanosine} under basic conditions which afforded [RuII(NH3)5(dGuo)]2+ 
and[RuIV(NH3)4(NH2)(dGuo)]4+ [74], refer to equation(3): 
 
2[Ru(NH3)5(dGuo)]3+ + OH- → [Ru(NH3)5(dGuo)]2+ + [Ru(NH3)4(NH2)(dGuo)]4+ + H2O      (3) 
 
Ruthenium(II) complexes disproportionate seldom, but an unusual proton induced 
disproportionation of the metal complex, RuII(NH3)2(bqdi)Cl2 (bqdi = o-
benzoquinonediimine), have been studied. Kapovsky et al. reported that the complex 
[RuII(NH3)2(bqdi)Cl2] undergoes disproportionation when exposed to UV-Vis light, to 
generate two final ruthenium(III) species, refer to equation (4) and (5). At first, an 
intermediate, [RuIV(NH3)2(opda)Cl2]2+ (opda = 1,2-phenylenediamine) is formed bythe 
protonation of the diimine nitrogen donors of the bqdi group. The intermediate 
influences the oxidation of the residual molecules of [RuII(NH3)2(bqdi)Cl2]  to produce 
the complex cations, [RuIII(NH3)2(opda)Cl2]+ and [RuIII(NH3)2(bqdi)Cl2]+ [75]. 
 
[RuII(NH3)2(bqdi)Cl2]+ 2H+ → [RuIV(NH3)2(opda)Cl2]2+                                           (4) 
 
[RuIV(NH3)2(opda)Cl2]2+ + [RuII(NH3)2(bqdi)Cl2]2+ → [RuIII(NH3)2(opda)Cl2]+ + 






1.6  Coordination Chemistry of Ruthenium(II) and –(III) 
1.6.1 Ruthenium complexes with N, N-donor ligands 
Ruthenium displays a high affinity towards nitrogen donor atoms like pyridyl, imine 
and amine nitrogens [76]. For example, the reaction of a multidentate N-donor 
benzimidazole ligand, tris[benzimidazol-2-yl-methyl]amine (L1) (see Figure1.13), with 
trans-[RuCl2(PPh3)3] formed a distorted octahedral structure in which the Ru centre  
coordinate via (N3)benzimidazoleNamine donor set of the neutral L1 moiety while the chloro 
and PPh3 co-ligands occupy the axial positions. DFT simulations indicate that in the 
HOMO and HOMO(-1) configurations, the frontier orbitals of the L1 chelator are 

















Figure 1.13: Structures of the free L1 ligand and its corresponding complex cation illustrating 








1.6.2 Ruthenium complexes with N, O-donor ligands 
Numerous ruthenium complexes containing a combination of hard and soft donor 
atoms (nitrogen and oxygen) have been synthesized in literature due to their broad 
applications in the field of catalysis and other molecular transformations [78]. These 
donor atoms have been included in different classes of ligands ranging from Schiff 
bases to heterocyclic ligands which invariably alter the structural and electronic 
properties of these metal complexes [79]. Such as in the case of the diamagnetic 
ruthenium complex, cis-[RuCl2(L3)(PPh3)] (L3 = 2-[(2-pyridylmethoxy)methyl]quinolone) 














Figure 1.14: Structure of the transfer hydrogenation catalyst, cis-[RuCl2(L3)(PPh3)]. 
 
1.6.3 Ruthenium complexes with N, S-donor ligands 
Ruthenium complexes with multidentate ligands incorporating nitrogen and sulfur 






features [81]. For example, in the ruthenium(II) carbonyl complex, trans-
[RuH(CO)L4(PPh3)2] (L4 = 2-(3,4-dichlorobenzylidene)-N-ethylhydrazine 
carbothioamide), the L4 ligand binds in a bidentate manner to the metal centre forming 
a four membered chelate ring [82] (see Figure 1.15). The emission spectra of this hydride 
complex afforded a single intra-ligand relaxation (at 411 nm) while two peak maxima 
(close to 415 and 460 nm) are observed in the chloride analogue, trans-
[RuCl(CO)L4(PPh3)2]. The electronic relaxations of the chloride complex was assigned to 














Figure 1.15: Structures of trans-[RuH(CO)L4(PPh3)2] and its free-ligand L4. The coordinating 
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Materials and Methods 
 
2.1 Handling of Ruthenium 
Ruthenium tetroxide (RuO4) is typically formed when acidic solutions containing 
ruthenium are oxidized rapidly by good oxidants like MnO4- or hot HClO4 [1]. 
Alternatively, when ruthenium compounds are heated in air, this can potentially lead to 
the formation of RuO4 which is poisonous, volatile and may cause damage to the eyes 
as well as the respiratory system [2]. On that account, special precautions were taken 
into consideration during the handling of all ruthenium compounds including the use 
of latex gloves, a nose mask as well as a fume cupboard in which all the coordination 
reactions were carried out. 
 
2.2 Materials 
2.2.1 Metal precursor 
The metal precursor trans-[RuCl2(PPh3)3] (97% purity) was obtained from Sigma-
Aldrich and no further purification was conducted on this chemical. 
2.2.2 Commercially acquired chemicals 
All solvents and common salts were obtained from Merck SA. Reagent grade toluene 
was dried over sodium wire while other solvents and chemicals that were purchased 
from Sigma-Aldrich were used without any further purification. Ultrapure water was 



























Hydroxylamine hydrochloride 99% 
Piperidine 98% 
Sodium tetraborohydrate 98% 
Tetrabutylammonium hexafluorophosphate   99% 
2,2-di(4-tert-octylphenyl)-1-picrylhydrazyl (DPPH) 98% 
Griess reagent 98% 






2.3  Methods 
The infrared spectra were recorded on a Perkin-Elmer Spectrum 100 in the 4000 – 350 
cm1 range. The 1H and 31P NMR spectra were obtained using a Bruker Avance 400 MHz 
spectrometer. All NMR spectra were recorded in DMSO-d6. UV-visible spectra were 
recorded using a Perkin Elmer Lambda 25. The extinction coefficients (ε) are given in M-
1 cm-1. The X-band electron paramagnetic resonance (EPR) spectra were obtained at 298 
K from a Bruker EMX Ultra X-band spectrometer. Melting points were determined 
using a Stuart SMP3 melting point apparatus. Mass spectral analysis of the complexes 
was done both in positive and negative modes via the direct injection of the respective 
samples into the Water Micromass LCT Premier instrument equipped with a Time-of-
Flight (TOF) Mass spectrometer analyzer and an Electron Spray Ionization (ESI) source. 
Elemental composition of the complexes was determined using ThermoScientific Flash 
2000 CHNS/O Analyser. The conductivity measurements were determined at 295 K on 
a Radiometer R21M127 CDM 230 conductivity and pH meter. A solution of 0.745 g KCl 
in 1 L of ultrapure water was used as the standard solution. 
 
Voltammetry measurements were done using an Autolab potentiostat equipped with a 
three electrode system: a glassy carbon working electrode (GCWE), a pseudo Ag|AgCl 
reference electrode and an auxiliary Pt counter electrode. The Autolab Nova 1.7 
software was utilized for the operation of the potentiostat and data analysis. The 
ruthenium complexes were made up in 2mM solutions along with 
tetrabutylammonium hexafluorophosphate (0.1 M) as a supporting electrolyte. Between 
each measurement, the GCWE electrode surface was polished with a slurry of ultrapure 
water and alumina on a Buehler felt pad followed by rinsing with excess ultrapure 
water and ultra-sonication in absolute ethanol. Spectroelectrochemical data were 
attained using a room temperature Specac optically transparent thin-layer 
electrochemical (OTTLE) cell purchased from the University of Reading which was 







Figure 2.1: Cyclic Voltammogram for the Ferrocene Standard at 100 mV/s with the arrows 
showing scan direction. 
 
The experimental procedures of the radical scavenging studies were adapted from 
literature methods [3, 4]. All experiments were run in triplicate and the percentage 
radical scavenging activities were determined via the following equation: 
% Radical scavenging activity = [(Ac – Af) / Ac] х 100 
where Ac is the absorbance of the control (DPPH or NO radicals) and Af is the 
absorbance upon addition of the ligand or metal complex to the control. In turn, the IC50 
values of the respective ligands and their metal complexes were calculated from the 
individual percentage radical scavenging activities. Firstly, the UV-vis spectrum of the 
control (0.2 mM solution of DPPH) was measured and thereafter a 0.1 cm3aliquot of the 






shaken vigorously, left to stand for 20 minutes in the dark and thereafter their 
respective UV-vis spectra were measured.  
The NO radical assay was done using the following experimental procedure:  A 5 mM 
solution of sodium nitroprusside was prepared in a phosphate buffered saline solution. 
After an incubation period of 3 hrs, the Griess reagent (0.5 cm3) was added to 0.3 cm3 of 
the nitroprusside solution. The UV-vis spectrum of this mixture was taken (which 
constitutes the “control”). The sample solutions were prepared by adding 0.3 cm3 of 
sodium nitroprusside solution to 1 cm3 of the metal complex or the free ligand (30 µM 
in DMSO) and allowing the resultant mixtures to incubate for 3 hrs at room 
temperature. After the incubation period, 0.5 cm3 of the Griess reagent was added 
which was followed by analysis through UV-vis spectroscopic measurements. 
 
The X-ray data for the metal complexes were recorded on a Bruker Apex Duo 
equippedwith an Oxford Instruments Cryojet operating at 100(2) K and an Incoatec 
microsource operating at 30W power. Data was collected with Mo Kα (λ = 0.71073 Å) 
radiation at a crystal-to-detector distance of 50 mm. The following conditions were used 
for data collection: omega and phi scans with exposures taken at 30 W X-ray power and 
0.50º frame widths using APEX2 [5]. The data were reduced with the program SAINT 
[5] using outlier rejection, scan speed scaling, as well as standard Lorentz and 
polarization correction factors. A SADABS semi-empirical multi-scan absorption 
correction [6] was applied to the data. Direct methods, SHELX-2014 [7] and WinGX [8] 
were used to solve all structures.  
 
Computational calculations were conducted using the Gaussian 09W software [9]. The 
geometry optimization of metal complexes 1 in Chapter 6 were accomplished at the 






311G++ (d, p) basis set was applied to all the C, H, N, O, Cl and P atoms and the 
LANL2DZ basis set, which makes use of effective core potentials, applied to the metal 
center [10]. Prior to the calculation, the solvent molecules of recrystallization for 1 were 
omitted from the crystal structure and the resultant structure was used as the starting 
conformer. Good agreement was found between the optimized and geometrical 
parameters with the minor deviations attributed to the fact that gas phase optimized 
structures do not account for non-classical hydrogen bonding interactions or any short 
distance contacts. Using the optimized structure of the metal complex, the lack of any 
negative Eigen values in the frequency calculations confirmed that the structure is at a 
global minimum on the potential energy surface [11]. The simulated electronic 
spectrum of 1 was computed using Time Dependent (TD)-DFT calculations using the 
aforementioned functional and hybrid basis set. 
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Ruthenium(II) and -(III) complexes with Schiff base 
ligands containing Benz(othiazole/imidazole/oxazole) 




The discovery of NAMI-A, trans-[RuCl4(DMSO)(Im)](ImH) {ImH = imidazole}  as a 
potential metallopharmaceutical for metastatic cancer, has led to a renewed interest into 
the medicinal inorganic chemistry of ruthenium [1-7]. In particular, ruthenium 
complexes with N-donor heterocyclic ligands have been widely investigated due to 
their diverse biological activities [8-12]. From a coordination chemistry perspective, this 
class of ligand systems afford ruthenium complexes with unique coordination 
environments, owing to the diverse donor atom combinations and resulting metal 
chelation [13-16].In addition, they can have variable stereo-electronic properties arising 
from their ability to form neutral or multivalent anionic N-donor chelators which 
inevitably allows for stabilization of the metal centre both in low and high oxidation 
states [8-20]. 
 
In this chapter, we report the reactions of trans-[RuCl2(PPh3)3] with the Schiff bases 
derived from heterocyclic moieties  [N-((pyridine-2-yl)methylene)-1H-benzimidazole 
(bzpy), N-(2-hydroxybenzylidene)-benzothiazole (Hbsp) , N-(2-hydroxybenzylidene)-






Figure 3.1) to afford the ruthenium complexes: cis-[RuIICl2(bzpy)(PPh3)2] (1), 
[RuCl(bsp)2(PPh3)] (2), trans-[RuCl(bzp)(PPh3)2] (3) and cis-[RuIICl2(bxth)(PPh3)2] (4), 
respectively. Despite the similar skeletal structures of the ligands, ruthenium complexes 
with diverse structural features were isolated. This diversity is also manifested in their 
redox and electronic properties. 
X
N N OH
X = S  (Hbsp) 














3.2.1 Synthesis of ligands: 
3.2.1.1  N-((pyridine-2-yl)methylene)-1H-benzimidazole (bzpy) 
A mixture of 2-aminobenzimidazole (0.50 g; 3.76 mmol) and 2-pyridinecarboxaldehyde 






along with 1 cm3 of piperidine. The resulting yellow solution was allowed to cool to 
room temperature and concentrated under reduced pressure. Afterwards, dry toluene 
(40 cm3) was added to the solution and heated to reflux for 6 hours with a Dean-Stark 
apparatus. A yellow precipitate was filtered and washed with cold anhydrous toluene. 
Yield = 75 %; M.P. 236 – 238 °C; IR (νmax/cm-1): ν(N-H) 3051 (w), ν(C=N) Schiff base 1612 (s), 
ν(C=N)Heterocyclic 1587 (s); 1H NMR (295K/ppm/d6-DMSO): 12.82 (br, s, 1H, NH), 9.36 (s, 
1H, H6),  8.80 (d, 1H, H1), 8.03 (t, 1H, H3), 7.67 – 7.46 (m, 3H, H2, H10, H11), 7.24 – 7.17 
(m, 2H, H9, H12);13C NMR (295 K/ppm/d6-DMSO): 165.50, 153.67, 150.71, 137.82, 
127.01, 122.81, 122.16; UV–Vis (DCM, λmax/nm (ε, M-1cm-1)): 255 (sh, 2300); 284 (1980); 
360 (2480). 
 








3.2.1.2 N-(2-hydroxybenzylidene)-benzothiazole (Hbsp) and N-(2-hydroxybenzylidene)-
benzimidazole (Hbzp) 
The titled Schiff bases derived from salicylaldehyde were isolated from adapted 
experimental procedures attained from literature [21, 22].For Hbsp and Hbzp, the 
respective (1:1 molar ratio) condensation reactions of salicylaldehyde with 2-
aminobenzothiazole and 2-aminobenzimidazole were conducted in dry toluene heated 
until reflux under a nitrogen atmosphere and in the presence of catalytic amounts of 
piperidine. 
 
3.2.1.3  N-((thiophene-2-yl)methylene)-benzoxazole (bxth) 
A reaction mixture of 2-aminobenzoxazole (0.50 g; 3.73 mmol) and 2-
thiophenecarboxaldehyde (0.50 g; 4.47 mmol) was heated until reflux for 3 hours in 
methanol (20 cm3), along with 1 cm3 of piperidine. The resulting yellow solution was 
allowed to cool to room temperature and concentrated under reduced pressure. 
Afterwards, dry toluene (40 cm3) was added to the solution and the latter was heated to 
reflux for 6 hours with a Dean-Stark apparatus. The yellow solution was cooled in an 
ice bath to give a yellow precipitate which was filtered and washed with petroleum 
ether.  Yield = 72%; M.P. 134 - 137°C; IR (νmax/cm-1): ν(C=N) 1580 (vs), 
ν(thiophene)1503, 1450, 1416 (s);1H NMR (295K/ppm/d6-DMSO): 9.55 (s, 1H, H1), 8.08 – 
8.14 (dd, 2H, H2, H3), 7.64 – 7.73 (m, 2H, H4, H5), 7.33 - 7.40(m, 3H, H6, H7, H8). UV–Vis 


































3.2.2 Synthesis of metal complexes 
3.2.2.1  Cis-Cl, trans-P [RuCl2(bzpy)(PPh3)2] (1) 
A mixture of bzpy (0.0304 g; 0.1368 mmol) and trans-[RuCl2(PPh3)3] (0.100 g; 0.1368  
mmol) in dry toluene (20 cm3) was heated to reflux under a nitrogen atmosphere for 6 
hours (hrs). The volume of the resultant dark brown solution was reduced to half and 
then n-hexane was added dropwise to induce precipitation. In turn, the dark brown 
precipitate was recrystallized via slow diffusion in a dichloromethane and n-hexane [1:1 
(v:v)] solution which resulted in the formation of dark brown XRD quality 
parallelograms. Yield = 63 %; M.P. > 350 °C; IR (νmax/cm-1): ν(N-H) 3067 (w), 
ν(C=N)Heterocyclic 1635 (s), ν(C=N)Schiff base 1606 (s), ν(Ru-[PPh3]2) 696 (s); 1H NMR 
(295K/ppm/d6-DMSO): 8.97 (s, 1H, NH), 8.47 (s, 1H, H6),  7.66 – 7.60 (m, 4H, H1, H2, 
H3, H4), 7.58 – 7.54 (m, 4H, H9, H10, H11, H12), 7.43 – 7.38 (m, 15H, PPh3), 7.27 – 7.22 
(m, 15H, PPh3); 31P NMR (295K/ppm/d6-DMSO): 25.57; UV-Vis (DCM, (λmax/nm (ε, M-
1cm-1))): 301 (12800); 358 (sh, 10056); 410 (sh, 7620); 435 (sh, 5484); 576 (3218); 
Conductivity (DCM, 10-3 M):  15.51 ohm-1cm-2mol-1; Calcd for C49H40Cl2N4P2Ru: C, 
64.05; H, 4.39; N, 6.10%. Found: C, 63.97; H, 4.01; N, 6.32; TOF-MS (m/z): Calcd: 918.11 
[M]; Found: 848.16 [M-2Cl]. 
 
3.2.2.2  [RuCl(bsp)2(PPh3)] (2) 
A two molar ratio of Hbsp (0.0695 g; 0.2736 mmol) with respect to the metal precursor, 
trans-[RuCl2(PPh3)3] (0.100 g; 0.1368 mmol) were reacted together in refluxing toluene 
(20 cm3) for 6 hrs. After the addition of 10 cm3 acetonitrile to the mother liquor and from 
the slow evaporation of the resultant mixture, dark brown crystals were attained for X-
ray analysis. Yield = 66 %; M.P. = 236 – 238 °C;  IR (νmax/cm-1): ν(C=N)Schiff Base 1588 (m), 
ν(C=N)Heterocyclic 1531 (m), ν(C=C)1435 (s), ν(Ru-PPh3) 693 (s); UV-Vis (DCM, (λmax/nm 






10-3 M):  19.38 ohm-1cm-2mol-1; Calcd for C46H33ClN4O2PRuS2: C, 61.02; H, 3.67; N, 6.19%. 
Found: C, 60.56; H, 4.01; N, 6.39%; TOF-MS (m/z): Calcd: 905.05 [M]; Found: 905.05 [M]. 
 
3.2.2.3  Trans-[RuCl(bzp)(PPh3)2](3) 
The title compound was formed from the 1:1 molar ratio reaction of Hbzp (0.0324 g; 
0.1368 mmol) and trans-[RuCl2(PPh3)3] (0.1002 g; 0.1368 mmol) in (20 cm3) toluene (after 
6 hrs of refluxing).  From the slow evaporation of the mother liquor, brown needle-like 
crystals suitable for X-ray analysis were obtained after 3 days. Yield = 71 %; M.P. = 256 
– 258 °C; IR (νmax/cm-1): ν(N-H) 3062 (w), ν(C=N)Schiff Base 1679 (m), ν(C=N)Heterocyclic 1589 
(m), ν(C=C)1433 (m), ν[Ru-(PPh3)2] 691; UV-Vis (DCM, (λmax/nm (ε, M-1cm-1))): 270 (sh, 
17891); 320 (sh, 10863); 385 (sh, 7029); 544 (sh, 1790); 692 (863); Conductivity (DCM, 10-3 
M):  28.74 ohm-1cm-2mol-1; Calcd for C57H47P2ClRuON3: C, 69.26; H, 4.79; N, 4.25%. 
Found: C, 68.87; H, 4.54; N, 4.75%; TOF-MS (m/z): Calcd: 896.13 [M]; Found: 895.14 [M-
H]. 
 
3.2.2.4   Cis-Cl, trans-P [RuCl2(bxth)(PPh3)2](4) 
To a solution of bxth (0.0238 g; 0.104 mmol) in 10 cm3 of toluene and trans-
[RuCl2(PPh3)3] (0.100 g; 0.1368  mmol) in toluene (10 cm3) was heated until reflux for 6 
hrs. After cooling to room temperature, the solution was filtered and allowed to 
evaporate slowly at room temperature. After 2 days, dark brown crystalline material 
was collected by filtration, washed with diethyl ether and dried under vacuum. Yield = 
56%; M.P. = 232 – 235 °C; IR (νmax/cm-1): ν(C=N) 1536 (w), ν(thiophene)1481, 1432, 1392 
(m), ν[Ru-(PPh3)2]692 (vs); 1H NMR (295K/ppm/d6-DMSO): 7.66 – 7.54 (m, 4H, H2, H3, 
H4, H5), 7.45 – 7.38 (m, 15H, PPh3), 7.28 – 7.21 (m, 15H, PPh3) 7.20 – 7.14 (m, 3H, H6, H7, 
H8); 31P NMR (295K/ppm/d6-DMSO): 25.58; UV-Vis (DCM, (λmax/nm (ε, M-1cm-1))): 286 






3M): 35.90 ohm-1cm-2mol-1; Calcd for C48H38Cl2N2OP2RuS.C7H8: C, 64.96; H, 4.56; N, 
2.75%. Found: C, 64.60; H, 4.55; N, 2.51%; TOF-MS (m/z): Calcd: 924.82 [M]; Found: 
591.04 [M-2Cl-1PPH3]. 
 
3.3 X-ray diffraction 
The X-ray data for the metal complexes 1-3 were recorded on a Bruker Apex Duo 
equipped with an Oxford Instruments Cryojet operating at 100(2) K and an Incoatec 
microsource operating at 30 W power. Crystal and structure refinement data are given 
in Table 3.3 while the selected bond lengths and angles are given in Tables 3.4, 3.5 and 
3.6. In all three cases the data were collected with Mo Kα (λ = 0.71073 Å) radiation at a 
crystal-to-detector distance of 50 mm. The following conditions were used for the 
Bruker data collection: omega and phi scans with exposures taken at 30 W X-ray power 
and 0.50º frame widths using APEX2 [23]. The data were reduced with the programme 
SAINT [23] using outlier rejection, scan speed scaling, as well as standard Lorentz and 
polarisation correction factors. A SADABS [24] semi-empirical multi-scan absorption 
correction was applied to the data [25].Direct methods, SHELXS-97 [25] and WinGX [26] 
were used to solve all three structures. All non-hydrogen atoms were located in the 
difference density map and refined anisotropically with SHELXL-97 [25]. All hydrogen 
atoms were included as idealised contributors in the least squares process. Their 
positions were calculated using a standard riding model with C-Haromatic distances of 
0.93 Å and Uiso = 1.2 Ueq.  The imidazolium N-H bonds of 1 and 2 as well as the toluene 
solvate C-H bonds of 3 were located in the difference density map, and refined 
isotropically.  All hydrogen atoms of 1 and 2 were included as idealized contributors in 
the least squares process but for 3, OLEX 2 was utilized where the hydrogen atoms 







3.4 Results and Discussion 
3.4.1 Synthesis and spectral characterization of  1, 2 and 3 
The equimolar ratio reactions of bzpy and Hbzp with trans-[RuCl2(PPh3)3] afforded a 
diamagnetic complex cis-Cl, trans-P-[RuIICl2(bzpy)(PPh3)2] (1) and a paramagnetic 
complex trans-[RuIII(bsp)Cl(PPh3)2] (3), respectively. In addition, a ‘2+2’ paramagnetic 
ruthenium (III) complex, [RuCl(bsp)2(PPh3)] (2) was attained from the 1:2 molar ratio 
reaction between trans-[RuCl2(PPh3)3] and Hbsp. The isolated ruthenium(II) and -(III) 
complexes exhibits diverse structural features, despite the fact that similarly structured 
ligand systems were reacted with the same metal precursor.  Both 1 and 3 are stabilized 
by the trans axial-[RuX-(PPh3)2] core {X = II (for 1) and X = III (for 3)}. In 1, the bzpy 
chelator acts as a neutral bidentate chelator through the imino (N1) and pyridyl (N2) 
nitrogens, whereas in 3, the coordinated bsp chelator acts as a dianionic tridentate 
chelator through the deprotonated imino carbon (C8) and phenolic oxygen (O1) as well 




































It is commonly found that multidentate Schiff base ligands stabilize the trans-
[RuII(PPh3)2]2+ core through their chelation and diverse donor capabilities. For example, 
the metal carbonyl complex trans-[RuH(cops)CO(PPh3)2] {Hcops = 2-
chlorophenylsalicylaldimine}, where the cops Schiff base moiety acts as a monoanionic 
bidentate chelator, affords a stable 6-membered chelate ring through the deprotonated 
phenolic oxygen and imino nitrogen [28]. This is further exemplified, within the 
bicyclometalled complex, trans-[Ru(mbo)CO(PPh3)2] {H2mbo = 2-
mercaptophenylimino-4-bromophenol}, in which the mbo Schiff base chelates the metal 
centre via the SNO donor set thereby forming 5- as well as 6-membered chelate rings 
[29].In another study, efforts to isolate a ruthenium complex with the potentially 
tetradentate bis-Schiff base ligand H2pmb, {1,2-bis(2’-pyridylmethyleneimino)benzene}, 
the ligand transformed  when reacted  with trans-[RuCl2(PPh3)3] to afford the dicationic 
complex cation trans-[Ru(PPh3)2(pbz)2](ClO)2 {pbz = 2-pyridylbenzimidazole} [30]. 
 
The metal complexes 1, 2 and 3 exhibit good solubility in most polar aprotic solvents 
but partial solubility in alcoholic media. The low molar conductivities of the respective 
complexes are typical of charge neutrality for ruthenium(II) and -(III) complexes 
[31].The 1H NMR spectrum of 1 is dominated by the intense signals of the 
triphenylphosphine co-ligands which appear as two separate multiplets (at 7.43 – 7.38 
ppm and 7.27 – 7.22 ppm) (see Figure3.6). More up-field, the aromatic signals of the 
pyridyl and benzimidazole moieties resonate as less intense multiplets [7.66 – 7.60 ppm 
and 7.58 – 7.54 ppm] respectively. Shifts in both the imidazolium [NH at 8.97 ppm] and 
imino [H6 at 8.47 ppm] protons of 1 relative to the corresponding signals found within 
the free-ligand’s 1H NMR spectrum (Schiff base and imidazolium protons found at 
12.82 and 9.36 ppm, respectively) affirms coordination of the bzpy chelator. Only one 
signal at 25.57 ppm is found for the two triphenylphosphine co-ligands which indicate 







Figure 3.6: 1H NMR spectrum of complex 1. 
 
 







Within the IR spectra, the single Ru-P bond of 2 [693 cm-1] shows a strong vibrational 
mode at nearly the same frequency as the trans-[Ru(PPh3)2] unit in 1 [696 cm-1] and 
3[692 cm-1] (see Figure 3.8 – 3.10). IR spectral analysis also confirmed coordination 
through the shifting of the C=N bands of the free–ligands in comparison to the 
corresponding bands found within the spectra of their complexes. 
 
 
Figure 3.8: Overlay IR spectra of complex 1 and its free ligand (bzpy) between 2000 and 650 
cm-1. 
 
For 1, the C=N bands of heterocyclic [1635 cm-1] and Schiff base [1606 cm-1] moieties 
appear at higher frequency compared to the same bands found in the free ligand’s 
[bzpy] IR spectrum [1612 cm-1 and 1587 cm-1].  Similarly for 3, the C=N [1679 cm-1 and 
1589 cm-1] bands are more red-shifted with respect to the bands of the free-ligand [1605 






at low frequencies in comparison to analogous C=N stretches within in the Hbsp 
spectrum [1679 and 1573 cm-1].  Weak intensity bands are found both in the IR spectra 












Figure 3.10: Overlay IR spectra of complex 3 and its free ligand (Hbzp) between 2000 and 650 
cm-1. 
 
Although a soft-ionization technique was employed, the positive mode mass spectrum 
of 1 showed a peak corresponding to a fragment of the complex minus the chloro co-
ligands (see Figure3.11). The peaks of 2 and 3 are detected at 905.049 m/z [M] and 









Figure 3.11: ESI-TOF-Mass spectrum of 1,with the inset showing an expanded region between 
790 and 910 m/z. 
 







Figure 3.13: ESI-TOF-Mass spectrum of 3. 
 
A series of intra-ligand π-π* transitions [301, 358, 410 and 435 nm] are observed in the 
UV-Vis spectrum of 1 which were similar to that of the free ligand’s electronic 
transitions (see Figure 3.14). A metal-to-ligand-charge transfer transition (MLCT) is 
observed at 576 nm while no d-d transition was found at longer wavelengths which are 
as expected for a low spin d6 octahedral complex [31]. Characteristic of 1, the highly 
delocalized chelators afford multiple π-π* transitions below 400 nm in the UV-Vis 
spectra of both complexes 2 and 3 (see Figure 3.15). Above 400 nm, MLCT [524 (for 2) 
and 544 (for 3) nm] and d-d [705 (for 2) and 692 (for 3) nm] transitions are found with 







Figure 3.14: Overlay UV-Vis spectra of complex 1 and its free ligand, bzpy. 
 
Figure 3.15: Overlay UV/Vis spectra of complexes 2 and 3 as well as their respective free 






The paramagnetic centres of complexes 2 and 3 were confirmed by room temperature 
X-band ESR spectroscopy. The anisotropic solid state ESR spectrum of 2 is nearly 
identical to the classical rhombic ESR spectra attained for low-spin ruthenium(III) Schiff 
base complexes; see Figure 3.16 [32, 33]. 
 
Figure 3.16: Solid state and solution X-band ESR spectra of 2 at 298 K. Instrument settings: 
microwave bridge frequency, 9.8 GHz; microwave bridge attenuator, 20 dB; modulation 
frequency, 100 kHz; modulation amplitude, 5 G; centre field, 3500 G. 
  
The deviation (between 3130 and 3370 G) from the typical rhombic ESR spectrum 
reflects distortion of the octahedral geometry for 2 [34, 35].The same phenomenon was 
observed within the poorly resolved solid state ESR spectrum of 3, where only gx- and 
gy- values were observed, refer to Table 3.1 and Figure 3.17.  In the case of the isotropic 
solution ESR spectra of 2 and 3 in dichloromethane: toluene (1:1), both compounds 
exhibit broad first derivative features devoid of additional fine structure with 







Figure 3.17: Solid state and solution X-band ESR spectra of 3 at 298 K. Instrument settings: 
microwave bridge frequency, 9.8 GHz; microwave bridge attenuator, 20 dB; modulation 
frequency, 100 kHz; modulation amplitude, 5 G; centre field, 3500 G. 
 
Table 3.1: G-values of the respective complexes in the solid state (A) and in solution (B). 
Spectrum gx gy gz giso 
2-A 2.198 2.090 1.910 - 
2-B - - - 2.113 
3-A 2.309 2.018 - - 
3-B - - -  2.1101 








3.4.2 Synthesis and spectral characterization of 4 
The equimolar reaction of the ligand bxth and trans-[RuCl2(PPh3)3] afforded the 
diamagnetic ruthenium(II) complex, cis-Cl, trans-P-[RuIICl2(bxth)(PPh3)2] (4) in 
moderate yield. Although this complexwas recrystallized from a 1:1 (v:v) 
dichloromethane: hexane solution using both slow and vapour diffusion methods, no X-
ray quality crystals could be obtained. Compound 4 is non-electrolyte in DCM, 
moderately soluble in polar solvents such as methanol, ethanol and acetonitrile but 
readily soluble in DMSO and DMF. 
 
This complex was characterized by infrared spectrometry, NMR (1H and 31P) 
spectroscopy, melting point measurements, elemental analysis and mass spectrometry. 
The IR spectrum of 4 confirms the presence of thetrans-[Ru(PPh3)2] unit by the 
occurrence of an intense stretch at 692 cm-1 found within the IR spectrum(see Figure 
3.18).Upon coordination of the bxth chelator to the metal centre, the acidic metal centre 
removes electron density from the imine double bond resulting in the weakening of the 
imine bond and hence the ν(C=N) appears as a weak intensity vibration band at 1536 
cm-1 which is found at lower frequency when compared to the ν(C=N) [at 1580 cm-1] of 
the free ligand bxth. Indicative to the aforementioned phenomena, when comparing the 
imine stretches of the free-ligand and chelator, significant shifts are also noticed in the 
thiophene vibrations (1503, 1450, 1416 cm-1) associated with the free-ligand, bxth and 
analogous vibrational bands (1481, 1432 and 1392 cm-1) of the bxth chelator. In turn, this 
IR spectral observation provides an indication that the thienyl sulfur is coordinated to 
the ruthenium centre [36]. Furthermore, the 1H NMR spectrum for the diamagnetic 
complex of 4 is dominated by multiplets (7.45 – 7.21 ppm) due to the 
triphenylphosphine co-ligands which are well clearly confirmed by 31P NMR 






The upfield shifts of the aromatic signals of the benzoxazole and thiophene moieties in 4 
relative to those of the free ligand affirm coordination. In the UV-Vis spectrum of 4, no 
d-d transition is observed at longer wavelength but a metal to ligand charge transfer 
transition (MLCT) at 476 nm with low extinction coefficient is seen (see Figure 3.21). 
The elemental analysis data and mass spectral analysis provided definitive insight into 
the structural elucidation. More specifically, the low resolution mass spectrum in the 
positive modeshowed a peak corresponding to a fragment of the complex minus the 
chloro co-ligands and one of triphenylphosphine co-ligands (see Figure 3.22). Thus 
taken into account the spectral characterization, the proposed structure of 4 is 
comprised of a trans-[Ru(PPh3)2] core with the equatorial plane being occupied by the 












Figure 3.19: 1H NMR spectrum of complex 4. 
 
 







Figure 3.21: Overlay UV-Vis spectra of complex 4 and its free ligand, bxth. 
 








Selected cyclic voltammogram (CV) parameters of the metal complexes 1-4 are 
summarized in Table 3.3 and their respective CVs are shown in Figures 3.23–3.26. The 
CVs of 1 and 3 showed one redox couple each whereas the CVs of 2 and 4 showed two 
redox couples labelled A and B. For 2, the peak potentials on the squarewave 
voltammogram (SWV, see Figure 3.27) are as expected equal to the calculated halfwave 
potentials. All the redox couples are quasi-reversible since their peak to peak 
separations (ΔE) are different from ferrocene (ΔE = 90 mV at 100 mV/s). In addition, all 
the redox couples showed diffusion controlled behaviour with increasing scan rates. 
This is illustrated by the overlay CVs of complex 3 for which scan rates ranged from 50 
mV/s to 200 mV/s, at increments of 25 mV/s(see Figure 3.28). Peak current ratios 
approaching one, were observed for all the complexes which imply that the redox 
couples are for one electron redox processes.  
 
The quasi-reversible redox processes of 1 and 3 were ascribed to the Ru(II/III) redox 
couples since they have similar halfwave potentials (E½) found for other 
ruthenium(II/III) complexes in the literature. Like in the case of the ruthenium(II) 
complexes, trans-[Ru(HRbmp)(PPh3)2(CO)(Cl)], 2-(benzylimino-methyl)-4-R—phenol 
(HRbmp) in DCM (vs Ag|AgCl) with halfwave potentials ranging from 0.62 V to 1.16 V 
[37].Similarly, the paramagnetic trans-[RuIIICl(L)(PPh3)2] {Schiff base (H2L) ligands 
derived from benzaldehyde and various functionalized acetic hydrazides} complexes 
exhibited comparable Ru(II/III) redox couples, under similar experimental conditions 
[38]. 
 
The two redox processes (A and B) of 2 were both assigned to be metal based redox 






redox active within the same potential window as A and B, respectively. These redox 
couples were assigned to the Ru(II/III) [for A] and Ru(III/IV) [for B] couples, consistent 
with analogous electrochemical behaviour as the ruthenium(III) bipyridine (bpy) 
complexes, [Ru(bpy)Cl3(X)] {X = MeOH, PPh3, 4, 4’-bipyridine or CH3CN} [39]. It has 
been noted, that the literature range of the halfwave potential differences (ΔE½) for 
mononuclear ruthenium complexes is 1.2 – 1.7 V. Within this study, a ΔE½ of 1.358 V for 
complex 2 was attained which supports the assignments of the respective couples. 
Table 3.2: Selected CV parameters (at 100 mV/s) for the complexes 1, 2, 3 and 4. 
Complex 1 2 3 4 
A B A B 
Epa/V 0.896 -0.433 0.965 0.660 -0.022 0.767 
Epc/V 0.820 -0.497 0.899 0.739 -0.111 0.657 
E½/V 0.858 -0.465 0.932 0.700 -0.067 0.712 
ΔE/mV 76 64 66 79 89 110 
 
 







Figure 3.24: CV of complex 3 at 100 mV/s between the potential range of 0.3 V and 1.1 V 
 
 







Figure 3.26: CV of complex 2 at 100 mV/s between the potential range of -1.0 V and +1.2 V. 
 







Figure 3.28: Overlay voltammograms of complex 3 from 50 mV/s to 200 mV/s at 25 mV/s 
increments. 
The redox couples of the respective complexes were further investigated with 
spectroelectrochemistry to corroborate the voltammetric assignments. The overlay UV-
Vis spectra of 1 showed a distinctive isosbetic point at 603 nm which is due to the 
appearance of a shoulder (at 681 nm) ascribed to a d-d electronic transition (see Figure 
3.29). Occurrence of this metal-based electronic transition implies that the d6 to d5system 
conversion transpired, confirming the Ru(II/III) redox couple in the CV assignment 
[40]. A characteristic feature is the accompanying decrease in the MLCT (at 576 nm) and 







Figure 3.29: UV-Vis spectral changes observed for reduction of complex 1 at an applied 
potential of -0.90 V. The initial spectrum is shown as a dashed blue line. 
 
Applying a controlled negative overpotential (at -0.55 V) for 2 while investigating the 
redox couple A, the reduction of the paramagnetic ruthenium(III) centre is confirmed 
by the disappearance of the d-d transition (at 705 nm) and the formation of a new MLCT 
band at 574 nm between the two defined isosbestic points (at 447 and 649 nm), see 
Figure 3.30. Another study of a ruthenium (III) complex, [Ru(H2bpyp)(acac)] {H2bpyp = 
1, 2-benzyl-bis-(2-(pyrazol-4-yl)phenol)}, with similar CV traces as 2 showed that the 
reduction to the Ru(II) species also resulted in the formation of a new MLCT [43]. 
 
Nearly quantitative conversion back to 2 occurred when a zero potential was applied, 
leading to the regeneration of the d-d transition. At incrementing applied positive 






at 259 nm and 286 nm while a decrease in the rest of the bands were noted(see Figure 
3.31), which could imply that ligand-induced oxidation of the metal centre took place 
[44, 45]. These spectroelectrochemical observations of 2 confirm the CV and SWV 
assignments for redox couples A and B. Unfortunately for 3, upon applying potentials 
between 0.865 V and 0.90 V, only diffuse isosbetic points were observed which is typical 
of the presence of two species within the solution. 
 
Figure 3.30: UV-Vis spectral changes observed for reduction of complex 2 at potentials of redox 








Figure 3.31: UV-Vis spectral changes observed for reduction of complex 2 at potentials of redox 
couple B, at incrementing applied potentials. The initial spectrum is shown as a dashed blue line. 
 
3.4.4 Crystallographic Studies 
Complexes 1 and 3·C7H8 crystallize in the space group P-1, with two molecules of each 
occupying the respective triclinic unit cells (i.e. Z = 2) whereas four crystallographically 
identical molecules of 2 (i.e. Z = 4) are found within its monoclinic unit cell (see Figures 
3.32–3.34). Similar crystal packing arrangements were observed for complexes 1 and 
3·C7H8: two mutual classical hydrogen bonds [N2-H2···N3 = 2.11294 Å] in 1 occur 
between two respective molecules resulting in a series of molecules aligned parallel 
with the [c]-axis; stabilization of the crystal lattice of 3 is rendered through non-classical 
hydrogen-bonding which allows the molecules to stack in columns along the [c]-axis. 
The molecules of 2 runs parallel with the [a]-axis due to a series of intermolecular 






Crystallographic distortion of 1 was observed on one of the phenyl groups of the 
P(2)Ph3 co-ligand. This distortion is ignored as it doesn’t influence the coordination 
behaviour of the bzpy chelator.   
 
The effects of cyclometallation are clearly evident from the distortion of the equatorial 
bond angles compared to the ideal octahedral values. For 1, the constrained N1-Ru-N2 
[78.45(5)⁰] bite angle forces the Cl1-Ru-Cl2 [91.44(1)⁰], Cl2-Ru-N2 [90.87(4)⁰] and [Cl1-
Ru-N1 = 99.24(4)⁰] bond angles wider than the idealized 90⁰ (see Figure 3.35). Similarly, 
the bicyclometalled complex 3 with its two 5-membered chelate rings [bite angles: N1-
Ru1-C8 = 76.0(2)⁰ and C8-Ru1-O1 = 80.8(1)⁰] force the bond angles Cl-Ru1-C8 = 
176.4(1)⁰ and N1-Ru1-O1 = 155.8(1)⁰ to deviate from linearity (see Figure 3.36). The 
same phenomenon was observed with complex 2’s equatorial bond [Cl1-Ru1-N3 = 
172.76(4)⁰ and O1-Ru1-O2 = 177.69(5)⁰] angles which were less than 180⁰ as ascribed to 
the 6-membered chelate rings [N3-Ru1-O2 = 87.29(6)⁰ and N1-Ru1-O1 = 90.51(6)⁰] (see 
Figure 3.37).  
 
In fact, the latter bond angles induces a P1-Ru-N1 [175.42(5)⁰] axial bond angle which 
deviates from linearity. For 1, non-linearity of its axial bond angle [P1-Ru-P2 = 
174.37(1)⁰] is ascribed to the interactions between selected phenyl rings of the PPh3 co-
ligands and the imidazolium/pyridyl moieties of the bzpy chelator, see Figure 3.38 {I = 
3.748 Å, II = 3.553 Å and III = 3.575 Å}. Consequently, the respective non-coordinating 
heterocyclic moieties are found out of plane with the pyridyl (of 1) and deprotonated 
phenolic (of 2) rings. More specifically, the pyridyl moiety of 1 is slightly out of plane 
(by 11.07°) with respect to the benzimidazole moiety. Furthermore, the benzothiazole 
moieties of 2 are at different angles [54.72˚ with respect to the S1-benzothiazole ring and 
11.53˚ with respect to the S2-benzothiazole ring] out of the plane of the deprotonated 






steric interactions. Unlike 1 and 2, no co-planar phenyl rings of the PPh3 co-ligands 
were found with respect to the bzp chelator of 3 which lead to a straighter backbone 
[P1-Ru1-P2 = 178.55(4)⁰]. The axial linearity of 3 is also clearly evident from the Ru-P 
[Ru1-P1 = 2.386(1) Å and Ru1-P2 = 2.407(1) Å] bond distance being nearly equal.  
 
The cis–chloro coordination bonds of 1 [Ru-Cl1 = 2.4369(3) Å and Ru-Cl2 = 2.4225(4) Å] 
are nearly equidistant which implies that the trans-influence on the N1 and N2 nitrogen 
atoms are approximately similar. The other coordination bonds, Ru-N1 [2.076(1) Å] and 
Ru-N2 [2.045(1) Å], are typical of a ruthenium(II) metal centre bonded to a pyridyl or 
Schiff base nitrogens, respectively. For example, the organoruthenium(II) complex, 
trans-Cl, cis-CO-[Ru(CO)2(spy)Cl2] {spy = N-((pyridine-2-yl)methylene)-thiazole} has 
similar Ru-NSchiff base and Ru-Npyridylbond lengths of 2.169(4) Å and 2.091(5) Å, 
respectively [46].Comparatively, the stronger Lewis acidic character of the 
paramagnetic ruthenium(III) centres compared to the diamagnetic metal centre of 1, 
afforded selected shorter analogous coordination sphere bonds for 2 [Ru1-P1 = 2.3536(5) 
Å, Ru1-N1 = 2.119(2) Å and Ru-N3 = 2.096(2) Å] and 3  [Ru-P1 = 2.386(1) Å, Ru-P2 = 
2.407(1) Å and Ru1-N1 = 2.069(4) Å]. However, the metal to chloride bond distances for 
2 [2.3634(5) Å] and 3 [2.436(1) Å] were different, which is largely due to the difference in 
the trans-influence experience by the various chloride ions. In addition, similar 
deprotonated phenolic oxygens to ruthenium (III) bond lengths were found for 2 [Ru1-
O1 = 1.975(1) and Ru1-O2 = 2.004(1)Å] and 3 [Ru1-O1 = 2.060(3) Å]. The difference in 
the imino coordination bonds of 2 are ascribed to the varied trans-influence on the 
imino nitrogens.  
 
The rare metal carbene [Ru1-C8 = 1.981(5) Å] bond distance (complex 3) were shorter 
than the analogous bond [Ru-CSchiff base= 2.048(7) Å] found in the ruthenium(II) complex, 






imino)methyl)benzoate} which is expected since the latter complex has a lower 
oxidation state [47]. Nitrogen heterocyclic carbene (NHC) ruthenium complexes have 
been widely researched due to their optimal catalytic properties, like in 
hydroformylation, olefin metathesis as well as hydrogen-transfer reactions [40, 41]. 
More recently, the first ruthenium chemotherapeutic drug, NAMI-A, trans-
[RuCl4(DMSO)(Im)](ImH) {Im = imidazole} has recently entered Phase II clinical trials 
due to its optimal antimetastatic cancer activity which is accompanied with fewer 
significant side effects than platinum-based metallopharmaceuticals [48]. This has led to 
an interest in exploring the biological activities of NHC ruthenium complexes, e.g., the 
NHC ruthenium(II) complexes, cis-[Ru(η6-cymene)Cl2(2R-bz)] {where R can be methyl, 
ethyl, isopropanol or  benzyl subsitituents on the nitrogen atoms of the bz moiety} have 
shown to exhibit various biological activities ranging from DNA intercalation to 
protease inhibitor capabilities [49]. 
 
Similar bond lengths were attained for the individual {C=N}Schiff base [C6-N1 = 1.311(2) Å 
(for 1) and C8-N3 = 1.326(6) Å] (for 3)] and {C=N}Heterocyclic [C7-N4 = 1.325(2) Å (for 1) 
and C7-N1 = 1.333(6) Å (for 3)] bond distances as the nitrogen atoms are sp2 hydridized 
nitrogens; but the aforementioned C=N bonds were still shorter than the carbon to 
sp3hybridized nitrogen bonds within their individual heterocyclic moieties [C7-N3 = 
1.357(2) Å (for 1) and N2-C7 = 1.360(6) Å (for 3)]. Within the bsp chelators (of 2), the 
imino bond [N3-C21 = 1.310(2) Å and N1-C7 = 1.296(2) Å] distances were typical for 
ruthenium(III) complexes with Schiff base chelates [50]; while the C=N bond [C8-N2 = 
1.297(2) Å and C22-N4 = 1.287(2) Å] (within the benzothiazole rings) lengths were 
shorter despite having the same bond order, but were comparable to transition metal 















Figure 3.33: Unit cell packing diagram for 2; Hydrogen atoms have been omitted for clarity. 
 
 









Figure 3.35: An ORTEP view of complex 1 showing 50 % probability displacement ellipsoids 










Figure 3.36: An ORTEP view of complex 3·C7H8 showing 50 % probability displacement 









Figure 3.37: An ORTEP view of complex 2 showing 50 % probability displacement ellipsoids 












Figure 3.38: Demonstration of the intramolecular π-π stacking interactions occurring in 













 Table 3.3: Crystal data and structure refinement data for 1, 2 and 3·C7H8.  
 1 2 3·C7H8 
Chemical formula C49H40Cl2N4P2Ru C46H33ClN4O2PRuS2 C57H47P2ClRuON3 
Formula weight 918.76 905.4 988.44 
Temperature(K) 100(2) 100(2) 100(2) 
Crystal system Triclinic Monoclinic Triclinic 
Space group P-1 P121/n P-1 
Unit cell dimensions (Ǻ, °) a = 12.2629(6) 
b = 13.4789(6) 
c = 14.8725(7) 
α= 104.012(2) 
β = 101.332(2) 
γ = 114.289(2) 
a = 12.6611(5) 
b = 23.4989(8) 
c = 13.1178(5) 
α = 90.00 
β = 91.807(2) 
γ = 90.00 
a = 11.9756(10) 
b = 12.7076(11) 
c = 15.1112(13) 
α= 97.670(4) 
β = 91.750(4) 
γ = 90.061(4) 
Crystal size (mm) 0.35 x 0.10 x 0.08 0.17 x 0.12 x 0.01 0.20 x 0.15 x 0.08 
V(Å3) 2048.54(17) 3900.89(4) 2278.0(3) 
Z 2 4 2 
Density (calc.) (Mg/m3) 1.490 1.54 1.441 
Absorption coefficient (mm-1) 0.63 0.665 0.519 
F(000) 940.00 1843.7 1018.0 
θ range for data collection (deg) 1.5; 30.53 1.7; 29.3 1.6; 27.08 
Index ranges -17 ≤ h ≤ 17 
-19 ≤ k < 19 
-21 ≤ ℓ ≤ 21 
-17 ≤ h ≤ 17 
-27 ≤ k < 32 
-18 ≤ ℓ ≤ 18 
-15 ≤ h ≤ 15 
-15 ≤ k < 16 
-18 ≤ ℓ ≤ 17 
Reflections measured 46486 42006 21774 
Observed reflections [I>2σ(I)] 12336 8949 7569 
Independent reflections 11489 10638 8917 
Data/Restraints/parameters 11489/0/582 10638/0/509 8917/0/587 
Goodness of fit on F2 1.044 1.036 1.117 
Observed R, wR2 0.0262; 0.066 0.031; 0.067 0.0564; 0.1404 
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Formation, electrochemical and radical scavenging 
properties of novel ruthenium compounds with N, X-
donor (X = O, N) heterocyclic chelators 
 
4.1 Introduction 
The concerted efforts in the isolation of new analogues of NAMI-A, trans-
[RuCl4(DMSO)(Im)](ImH) {ImH = imidazole} are due to its potent anti-metastatic 
cancer activity [1, 2]. Our interest is the utilization of heterocyclic-derived ligands 
incorporating benz(imidazole/othiazole/oxazole) moieties due to their multitude of 
biological activities [3-5]. In addition, the secondary metabolite, chromone and its 
organic and inorganic compounds have proven to exhibit potent anticancer activities 
against a wide range of cancer cell lines [6-9]. Most recently, we have also designed 
Schiff bases containing the tetrahydro-2H-pyrane moiety which shares the same 
backbone structure as the sugar derivative, mannose. Their structural similarities’ can 
potentially enforce the target specific binding of the tetrahydro-2H-pyrane-derived 
Schiff bases and their metal complexes to the mannose receptors in the Sentinel Lymph 
Node (SLN) [10]. 
 
This chapter details the formation of novel ruthenium compounds containing 
benzoxazole-amide, benzimidazole-amines and chromone-derived Schiff base ligands. 
The metal complexes: [RuCl(pho)(bzca)(PPh3)] (1) (pho = 2-aminophenolate; bzca = 2-
carboxylate-1H-benzimidazole), cis-Cl, trans-P-[RuIII(Hbhb)Cl2(PPh3)2] (2), (μ-






from the reactions of trans-[RuCl2(PPh3)3] with 2-((1H-
benzimidazole)methylamino)phenol (Hbzap), N-(benzoxazole)-2-hydroxybenzamide 
(H2bhb), N-(thiophene)methyl-benzoxazole-2-amine (Htba) and 2-amino-3-((tetrahydro-
2H-pyran-4-ylimino)methyl)-4H-chromen-4-one (H2chpr), respectively (see Figure 4.1). 
Under similar experimental conditions, a diamagnetic complex, [RuIICl2(Hbzpy)(PPh3)2] 
(5) was also formed using N-((pyridine-2-yl)methyl)-1H-benzimidazole (Hbzpy) with 
the same metal precursor. In addition, the redox properties of the metallic compounds 
1-5 investigated via voltammetric analysis were comparable to other ruthenium 
compounds found within the literature [11]. The metallic complexes 1-4 exhibit higher 




































4.2.1 Synthesis of ligands: 
4.2.1.1   2-((1H-benzimidazole)methylamino)phenol (Hbzap) 
A reaction mixture of 2-chloromethylbenzimidazole (2.50 g; 15 mmol), 2-aminophenol 
(1.64 g; 15 mmol) and KI (2.50 g; 15 mmol) in 75 cm3 of absolute ethanol was heated 
under reflux. After 6 hrs, a catalytic amount of KOH (0.84 g; 15 mmol) in 7.5 cm3 of 
distilled water was added drop wise with continuous stirring for 2 hours. Thereafter, 
the reaction mixture was allowed to cool down to room temperature and then poured 
into crushed ice water. Instantaneously, a brown precipitate formed which was 
recrystallized from ethanol to afford brown needle-like crystals. Yield = 92%; M.P. = 210 
– 212 °C; IR (νmax/cm-1): ν(N-H) 3043 (bz, m), 3003 (amine, w), ν(O-H) 2556 (w), ν(C=N) 
1517 (s), ν(C-N) 1239 (s); 1H NMR (295K/ppm /d6-DMSO):  12.32 (br, s, 1H, NH)bz, 9.40 
(s, 1H, NH)amine, 7.55-7.47 (m, 2H, H1, H4), 7.17 – 7.11 (m, 2H, H2, H3), 6.69 (d, 1H, H10), 
6.58 (t, 1H, H9), 6.51 – 6.42 (m, 2H, H7, H8), 4.49 (s, 2H, H5, H6), 3.33 (br, s, 1H, OH). 
UV-Vis (DMF, (λmax (ε, M-1cm-1))): 239 nm (sh, 28849); 282 nm (22435); 332 nm (27317); 
352 nm (29035); 385 nm (34243).  
 






4.2.1.2  N-(benzoxazole)-2-hydroxybenzamide (Hbhb) 
The reaction mixture of 2-aminobenzoxazole (0.25 g; 1.86 mmol) and salicylaldehyde 
(0.230 g; 1.86 mmol) dissolved in 40 cm3 of dry toluene containing 3 drops of piperidine 
was heated at reflux temperature for 6 hrs under nitrogen. The initial yellow solution of 
the reaction mixture turned orange and was allowed to cool down to room temperature 
after the reflux period and thereafter left overnight in the fridge in order to induce 
precipitation. The resultant yellow precipitate was filtered and washed with cold 
anhydrous toluene and petroleum ether. Yield = 80%; M.P. = 136 – 138 °C; IR (νmax/cm-
1): ν(N-H) 3339, ν(O-H) 3056 (w), ν(C=O) 1706 (m), ν(C=N) 1601 (vs), ν(C-N) 1244 (s); 1H 
NMR (295K/ppm/d6-DMSO): 9.68 (s, 1H, NH), 7.98 (d, 1H, H5), 7.75 – 7.67 (m, 2H, H2, 
H3), 7.54 (t, 1H, H4), 7.43 – 7.35 (m, 2H, H10, H11), 7.07 – 6.98 (m, 2H, H9, H12), 3.36 (br, 
s, 1H, OH); UV-Vis (DMF, (λmax (ε, M-1cm-1))): 241 nm (10974); 282 nm (8712); 330 nm 
(15707); 351 nm (16979); 383 nm (20673). 
 






4.2.1.3  N-(thiophene)methyl-benzoxazole-2-amine (Htba) 
The Schiff base, N-((thiophen-2-yl)methyleneimino)benzoxazole (Htbi) was isolated as 
an orange crystalline substance from the equimolar condensation reaction between 2-
aminobenzoxazole (0.250 g; 1.86 mmol) and 2-thiophenecarboxaldehyde (0.209; 1.86 
mmol). The reaction was conducted in 40 cm3 of dry toluene and in the presence 3 
drops of piperidine, under nitrogen for 6 hrs followed by reducing the reaction mixture 
to 5 cm3 and cooling it in an ice-bath to induce crystallization. The reducing agent, 
sodium borohydride (0.025 g, 0.66 mmol) in ethanol (10 cm3) was added dropwise to a 
stirring solution of ethanol (20 cm3) containing 0.15 g of Htbi (0.66 mmol) at room 
temperature. The reaction mixture was then refluxed for an hour and thereafter cooled 
to room temperature by adding an equal volume of cold distilled water. A white 
precipitate instantaneously formed which was collected, washed with distilled water 
and dried under vacuum.Yield = 88%; M.P. = 126 – 128 °C; IR (νmax/cm-1): ν(N-H) 3046 
(w),  ν(thiophene) 1459, 1439 sh, 1354, 1321 (s), ν(C-N) 1246 (s); 1H NMR (295K/ppm/d6-
DMSO): 8.50 (s, 1H, NH), 7.40 (d, 1H, H9), 7.35 (t, 1H, H8), 7.27 (d, 1H, H7), 7.15 – 7.06 
(m, 2H, H3, H4), 7.02 – 6.96 (m, 2H, H1, H2), 4.68 (s, 2H, H5, H6); UV-Vis (DMF, (λmax (ε, 








Figure 4.4: 1H NMR spectrum of Htba and inset showing the signals for the aromatic protons. 
 
4.2.1.4   2-amino-3-((tetrahydro-2H-pyran-4-ylimino)methyl)-4H-chromen-4-one 
            (H2chpr) 
A solution of tetrahydro-2H-pyran-4-amine (0.20 g; 1.98 mmol) in 20 cm3 of methanol 
was added dropwise to a stirring methanolic solution (20 cm3) of 2-amino-3-
formylchromone (0.37 g; 1.98 mmol).  The resultant reaction mixture was refluxed for 3 
hrs and then reduced down to 5 cm3 and cooled in an ice bath which resulted in the 
formation of yellow crystals of the titled compound. These crystals was washed with 
anhydrous petroleum ether and dried under vacuum. Yield = 86%; M.P. = 165 – 167 °C; 
IR (νmax/cm-1): ν(N-H) 3074 (m), ν(C=O) 1661 (s), ν(C=N) 1602 (vs), ν(C-O-C)chromone 1566, 
1490 (s), ν(C-O-C)tetrahydropyran 1139 (s); 1H NMR (295K/ppm/d6-DMSO): 8.93 (br, s, 2H, 






– 3.84 (m, 2H, H12, H12’), 3.39 – 3.53 (m, 2H, H15, H15’), 1.77 – 1.56 (m, 4H, H13, H13’, 
H14, H14’); UV-Vis (DMF, (λmax (ε, M-1cm-1))): 236 nm (19312); 267 nm (sh, 12843); 301 
nm (sh, 9134); 334 nm (7979); 350 nm (9253); 364 nm (sh, 7890). 
 
Figure 4.5: 1H NMR spectrum of H2chpr. Inset (a) showing the signals for the chromone 
protons. Inset (b) showing the signals for the tetrahydropyran aromatic protons. 
 
4.2.1.5  N-((pyridine-2-yl)methyl)-1H-benzimidazole (Hbzpy) 
An equimolar amount of sodium borohydride was added dropwise to a stirring 
solution of the Schiff base, N-((pyridine-2-yl)methylene)-1H-benzimidazole (bzpy) (0.15 
g; 0.68 mmol) in ethanol (20 cm3) at room temperature for over 24 hrs. Afterwards the 
reaction mixture was refluxed for 1 hr and cooled to room temperature. Thereafter, this 






minutes. A white precipitate was formed which was filtered, washed with distilled 
water and dried under vacuum.Yield = 89%; M.P. = 218 – 220 °C; IR (νmax/cm-1):ν(N-H) 
3242 (w), 3049 (w), ν(C-N) 1240 (s); 1H NMR (295K/ppm/d6-DMSO): 10.84 (s, 1H, NH), 
8.53 (d, 1H, H10), 7.74 (t, 1H, H9), 7.38 (d, 1H, H7), 7.26 (t, 1H, H8), 7.15 – 7.06 (m, 3H, 
H1, H4, NH), 6.92 – 6.79 (m, 2H, H2, H3), 4.61 (d, 2H, H5, H6); UV-Vis (DCM, (λmax (ε, M-















Figure 4.6: Numbering scheme for Hbzpy. 
 







4.2.2 Synthesis of metal complexes 
4.2.2.1  [RuCl(pho)(bzca)(PPh3)] (1) 
A reaction mixture of Hbzap (0.0250 g; 0.104 mmol) and trans-[RuCl2(PPh3)3] (0.1004 g; 
0.104 mmol) in toluene (20 cm3) was heated to reflux under a nitrogen atmosphere for 6 
hrs. A dark brown precipitate was collected via filtration, washed with anhydrous di-
ethyl ether and dried under vacuum. This precipitate was recrystallized via the slow 
diffusion of dichloromethane into a methanolic solution which yielded XRD quality 
dark brown crystals. Yield = 55%; M.P. = 250 – 252 °C; IR (νmax/cm-1): υ(N-H) 3050, 3025 
sh (m), υ(O-H) 2552 (w), υ(C=O) 1588 (m), υ(C=N) 1531, 1514 (vs), υ(Ru-PPh3) 693 (vs), 
υ(Ru-O, N)phenolate 466, 430 (s), υ(Ru-O, N)benzimidazole 541 (s), 511 (vs);UV-Vis (DCM, (λmax 
(ε, M-1cm-1))): 232 nm (sh, 31968); 272 nm (sh, 14474); 359 nm (sh, 9806); 435 nm (sh, 
6511); 470 nm (5848); 703 (sh, 1977).Conductivity (DCM, 10-3 M): 21.94ohm-1cm-2mol-1; 
Anal. Calc. for C33H29ClN3O4PRu (%): C, 56.69; H, 4.18; N, 6.01. Found: C, 56.74; H, 4.13; 
N, 6.16. 
 
4.2.2.2  cis-Cl, trans-P-[Ru(Hbhb)Cl2(PPh3)2] (2) 
The equimolar amounts of H2bhb (0.0249 g; 0.104 mmol) and trans-[RuCl2(PPh3)3] 
(0.1004 g; 0. 104 mmol) in dichloromethane (20 cm3) was allowed to stir for 24 hrs in an 
open atmosphere. A dark brown solution was obtained after which the volume was 
reduced and the product was precipitated by addition of n-hexane. The complex was 
recrystallized via slow diffusion of dichloromethane into a methanolic solution which 
resulted in the formation of brown crystals. Yield = 78%; M.P. = 255 – 257 ºC; IR 
(νmax/cm-1): υ(O-H) 3051 (w), υ(C=N) 1547 (s), υ(C-N) 1238 (s), υ[Ru-(PPh3)2] 691 (vs), 
υ(Ru-N) 451 (s), υ(Ru-O) 433 (m).1H NMR (295K/ppm): 7.68 – 7.52 (m, 30H, 2 x PPh3), 
7.43 – 7.38 (m, 4H, H10, H11, H12, H13), 7.27 – 7.21 (m, 4H, H2, H3, H4, H5), 5.09 (br, s, 






51784); 311 nm (37235); 351 nm (25117); 436 nm (8927); Conductivity (DCM, 10-3 M): 
26.89 ohm-1cm-2mol-1;Anal. Calc. for C50H39Cl2N2O3P2Ru (%): C, 63.23; H, 4.14; N, 2.95. 
Found: C, 62.55; H, 4.07; N, 3.22. 
 
4.2.2.3  (μ-Htba,Cl)2[RuIICl(PPh3)]2 (3) 
Compound 3 was isolated from the reaction of Htba (0.0240g; 0.104 mmol) and trans-
[RuCl2(PPh3)3] (0.1004 g; 0.104 mmol) in hot benzene (20 cm3) at reflux  under a nitrogen 
atmosphere for 6 hrs. The volume was reduced to 5 cm3 and the product precipitated by 
the addition of n-hexane. Recrystallization of the precipitate was achieved from the 
slow evaporation of a dichloromethane: methanol (1:1, v:v) solution giving solid dark 
brown cubic crystals. Yield = 63%; M.P. = 165 –167 °C; IR (νmax/cm-1): υ(N-H) 3052 (w), 
υ(C=N) 1649 (s), υ(thiophene, C=C) 1465, 1436 (s), 1366, 1339 (w), υ(C-N) 1246 (m), υ(Ru-
PPh3) 694 (vs), υ(Ru-N)benzimidazole  539 (vs), υ(Ru-N)amine 515 (vs);1H NMR (295K/ppm): 
8.84 (br, s, 2H, NH, NH’), 8.53 (t, 2H, H3, H3’), 7.84 (t, 2H, H2, H2’), 7.68 – 7.51 (m, 15H, 
PPh3), 7.45 – 7.32 (m, 15H, PPh3), 7.31 – 7.20 (m, 10H, Ar, Ar’ Toluene), 7.15 – 7.06 (m, 4H, 
H1, H1’, H4, H4’), 7.02 – 6.96 (m, 6H, H7, H7’, H8, H8’, H9, H9’), 4.68 (d, 4H, H5, H5’, H6, 
H6’), 2.08 (s, 6H, CH3, CH3’ of toluene); 31P NMR (295K/ppm): 25.55; UV-Vis (DCM, 
(λmax (ε, M-1cm-1))): 275 nm (sh, 67628); 404 nm (sh, 14805); 573 nm (9621). Conductivity 
(DCM, 10-3 M):  27.55 ohm-1cm-2mol-1; Anal. Calc. for C60H52Cl4N6P2Ru2S2 (%):C, 54.30; 
H, 3.95; N, 6.33. Found: C, 54.49; H, 3.60; N, 6.57. 
 
4.2.2.4  (µ-Cl)2[RuIIICl(Hchpr)(PPh3)]2 (4) 
The metal precursor, trans-[RuCl2(PPh3)3] (0.1004 g; 0.104 mmol), when reacted with 
H2chpr (0.0284 g; 0.104 mmol) dissolved in hot anhydrous toluene (20 cm3) at reflux 
temperature for 5 hrs under an open atmosphere, afforded a green mother liquor. From 






analysis were obtained after several days. Yield = 72%, M.P. = 262 – 264 °C. IR (νmax/cm-
1): υ(N-H) 3053 (w), υ(C=O) 1639 (m), υ(C=N) 1564 (vs), υ(C-O-C)chromone 1437 sh, 1433 (s), 
υ(C-O-C)tetrahydropyran 1136 (m), υ(Ru-PPh3) 692 (vs), υ(Ru-N)imino 513 (vs), υ(Ru-N)amindo 488 
(s). UV-Vis (DCM, (λmax (ε, M-1cm-1))): 257 nm (sh, 28589); 280 nm (sh, 17664); 305 nm 
(sh, 13147); 355 nm (9632); 465 nm (sh, 4315); 688 nm (sh, 2334); Conductivity (DCM, 10-3 
M): 22.73 ohm-1cm-2mol-1;Anal. Calc. for C80H76Cl4N4O6P2Ru2 (%):C, 60.23; H, 4.80; N, 
3.51. Found: C, 60.19; H, 4.78; N, 3.72. 
 
4.2.2.5  cis-[RuCl2(Hbzpy)(PPh3)2] (5) 
A solution of Hbzpy (0.0234 g; 0.104 mmol) and trans-[RuCl2(PPh3)3] (0.1004 g; 0.104 
mmol) in toluene (20 cm3) was heated at reflux temperature under a nitrogen 
atmosphere for 6 hrs. The volume was reduced to 5 cm3 and the product precipitated by 
addition of n-hexane. The complex was recrystallized from dichloromethane/n-hexane 
solution to give dark brown crystals. Yield = 60%; M.P. = 253 – 255 °C; IR (νmax/cm-1): 
υ(N-H) 3055 (w), υ(C-N) 1227 (m), υ(Ru-PPh3) 694 (vs), υ(Ru-N)amine 515 (vs);1H NMR 
(295K/ppm): 7.48 (t, 1H, H9), 7.72 (t, 1H, H8), 7.42 – 7.35 (m, 15H, PPh3), 7.28 – 7.20 (m, 
15H, PPh3), 7.18 – 7.12 (m, 3H, H1, H4, NH), 7.05 – 6.93 (m, 2H, H2, H3), 4.06 (d, 2H, H5, 
H6);31P NMR (295K/ppm): 28.92; UV-Vis (DCM, (λmax (ε, M-1cm-1))): 403 nm (5708); 582 
nm (1620); Conductivity (DCM, 10-3 M):  27.33 ohm-1cm-2mol-1; Anal. Calc. for 
C49H41Cl2N4P2Ru (%):C, 63.98; H, 4.49; N, 6.09. Found: C, 63.66; H, 4.10; N, 6.32. 
 
4.3 X-ray diffraction 
Crystal and structure refinement data are given in Table 4.3. Selected bond lengths and 
angles are given in Tables 4.4, 4.5 and 4.6 for 1, 2 and 4, respectively. Only a low 
resolution structure of 3 could be attained. In addition, one disordered toluene molecule 






three cases the data were collected with Mo Kα (λ = 0.71073 Å) radiation at a crystal-to-
detector distance of 50 mm. The following conditions were used for data collection: 
omega and phi scans with exposures taken at 30 W X-ray power and 0.50º frame widths 
using APEX2 [14]. The data were reduced with the programme SAINT [14] using outlier 
rejection, scan speed scaling, as well as standard Lorentz and polarization correction 
factors. A SADABS semi-empirical multi-scan absorption correction [15] was applied to 
the data. Direct methods, SHELX-2014 [16] and WinGX [17] were used to solve all three 
structures. All non-hydrogen atoms were located in the difference density map and 
refined anisotropically with SHELX-2014 [16]. All hydrogen atoms were included as 
idealised contributors in the least squares process. Their positions were calculated using 
a standard riding model with C-Haromatic distances of 0.93 Å and Uiso = 1.2 Ueq, C-Hmethylene 
distances of 0.99 Å and Uiso = 1.2 Ueq and C–Hmethyldistances of 0.98 Å and Uiso = 1.5 Ueq.  
The amine N-H and hydroxyl O–H were located in the difference density map and 
refined isotropically.  
 
4.4 Results and Discussion 
4.4.1 Synthesis and spectral characterization of 1, 2, 3 and 4 
The respective free ligands were attained in good yields and spectroscopic 
characterizations provided definitive insight into their individual molecular structures, 
see Figures 4.3–4.7 above. The metallic compounds exhibit remarkably good solubility 
in all chlorinated solvents and selected high boiling point aprotic solvents including 
dimethylformamide and dimethylsulfoxide but poor solubility in alcoholic media. The 
low molar conductivity values of the metallic compounds 1-4 are testimony to their 
electrical neutrality and these values were similar to other neutral ruthenium (II), – (III) 







A proposed route to the formation of 1 is illustrated in Scheme 4.1. The first step entails 
the equimolar ratio reaction between the metal precursor and ligand, Hbzap which 
afforded the ruthenium (II) intermediate, [RuCl(bzap)L2] (L = PPh3). Despite the use of 
an inert nitrogen atmosphere, dimolecular oxygen diffused into the refluxing toluene 
solution. In turn, the dimolecular oxygen in the presence of H+ ions and the 
ruthenium(II) intermediate afforded molecular hydrogen peroxide in the reaction 
mixture. This is supported by the patent of Diamond et. al., in which their study have 
shown that hydrogen peroxide can be generated by the oxidation of their formulated 
ruthenium(II) compounds to analogous ruthenium(III) compounds in the presence of 
dimolecular oxygen and H+ ions [19]. This is followed by C-N amine bond cleavage 
induced by hydrogen peroxide [20]. The residual hydrogen peroxide acts as co-catalyst 
with the ruthenium(III) intermediate, [RuCl(bzca)L2]+ which oxidizes the 2-methyl-1H-
benzimidazole carbo-anion to 2-carboxylate-1H-benzimidazole (bzca) [21, 22]. Then the 
bzca moiety coordinates to the ruthenium which oxidizes the metal centre to its +IV 
oxidation state. This ultimately led to the paramagnetic ruthenium (IV) centre of 1 being 
surrounded by the two bidentate chelators (viz. monoanionic bzca and dianionic pho), 
(see section 4.4.5.1, Figure 4.28).  
 
The Hbhb chelator of complex 2 acts as monoanionic bidentate chelator through the 
amide oxygen (O2) and benzoxazole nitrogen (N1) (see section 4.4.5.2, Figure 4.30). 
Furthermore, this mononuclear ruthenium complex 2 is stabilized by the trans-
[Ru(PPh3)2] core.  The metal centres of the dinuclear compounds 3 and 4 are bridged by 
chloro ligands while the former is reinforced by the bidentate coordination of the 
neutral Htba chelators through the benzimidazole and amine nitrogens to the respective 
metal centres (see section 4.4.5.3, Figures4.32 and 4.34). For compound 4, each 
monoanionic Hchpr chelator coordinates in a bidentate manner through their singly 






coordination spheres for each metal centre in 3 and 4 are completed by mono-














































Mutual intense stretches are observed in the IR spectra of all the metallic compounds [at 
693 cm-1 (for 1), 691 cm-1 (for 2), 694 cm-1 (for 3) and 692 cm-1 (for 4)] ascribed to the 
υ(Ru-PPh3) vibrations, (see Figures 4.8–4.11).  In addition, in the IR spectra of the 
respective metallic compounds, distinctive low intensity vibrations are also found 
below 600 cm-1 due to the Ru-N and Ru-O coordination bonds. The absence of the C-N 
stretch (at 1277 cm-1 for Hbzap) in the IR spectrum of 1 indicated that the Hbzap ligand 
has cleaved into bzca and pho moieties. Furthermore, the coordination of the bzca 
moiety is affirmed by the ν(C=N) vibration appearing as two splitted stretches 
compared to that of the free-ligand which is found at 1513 cm-1 as a broad single 
vibrational band.  For complex 2, the heterocyclic C=N vibrational band appears at a 
lower frequency (at 1547 cm-1) in comparison to the corresponding vibrational band of 
its free ligand occurring at 1601 cm-1.  Similarly for the dinuclear ruthenium compound 
4, evidence of coordination of its chelators, are given by the C=N vibrational band of 4 
shifting to lower frequencies [1564 cm-1 for 4 and 1602 cm-1 for H2chpr]. For complex 3, 
the C-N amine vibration is at a common frequency (at 1246 cm-1) with respect to the 






Figure 4.8: Overlay IR spectra of complex 1 and its free ligand, bzap between 2000 and 370 
cm-1. 
 








Figure 4.10: Overlay IR spectra of compound 3 and its free ligand, Htba between 2000 and 370 
cm-1. 
 







Proof of chelation can also be attained from NMR spectral analysis of the diamagnetic 
compound 3. The Htba ligands exhibit magnetic equivalence given by the fact that the 
signals resonate at the same position and that each signal integrates to double of that 
what is expected for one Htba chelator, (see Figure 4.12). For example, a broad singlet is 
observed at 8.84 ppm for the amine protons (for NH and NH’) whereas for the free-
ligand, Htba a broad singlet integrating to one is found at 8.50 ppm for the amine 
proton. For 3, the signal of the respective triphenylphosphine co-ligands does not 
coalesce but rather appear as two intense multiplets each integrating to 15 protons. 
Despite the trend observed with respect to the triphenylphosphine co-ligands in the 
proton NMR spectrum of 3, the phosphorous signals of 3 (at 25.55 ppm) appear as a 
single peak indicating magnetic equivalence.  
 
 
Figure 4.12: 1H NMR spectrum of compound 3 between 7.65 and 6.94 ppm. Inset: The low 






Several common π-π* intraligand transitions are observed below 400 nm in the overlay 
UV-Vis spectra of the free ligands and their metallic compounds 1-4, (see Figures 4.13-
4.16). In addition, at red-shifted wavelengths between 400 and 600 nm, Ligand-to-
Metal-Charge-Transfer (LMCT) bands are found. As expected, the low spin d6 metallic 
compound 3 has no metal-based electronic transitions while for the paramagnetic 
ruthenium(III) compounds  1 and 4: a distinctive d-d transition for compound 4 (at 688 
nm) and a shoulder with a low extinction coefficient for complex 1 (at 703 nm) is 
observed. However, for the d5 complex 2, no d-d transition was observed which could be 




Figure 4.13: Overlay UV/Vis spectra of complex 1 and its free-ligand, bzap. Inset: The d-d 







Figure 4.14: Overlay UV/Vis spectra of complex 2 and its free-ligand, Hbhb. 
 
 







Figure 4.16: Overlay UV/Vis spectra of compound 4 and its free-ligand, H2pchr. 
 
4.4.2 Synthesis and spectral characterization of 5 
Complex 5 was synthesized from the 1:1 molar ratio reaction between trans-
[RuCl2(PPh3)3] and Hbzpy to give a diamagnetic ruthenium complex, cis-
[RuIICl2(Hbzpy)(PPh3)2]. However, an X-ray crystal structure analysis of the metal 
complex could not be attained as the cubic crystal of 5 did not diffract using single 
crystal X-ray diffractometry. This metal complex is a non-electrolyte complex in DCM 
and it is soluble in a variety of polar solvents including chlorinated solvents. Indicative 
to what is observed in the IR spectra of metal complexes 1–4, the presence of thetrans-
[Ru(PPh3)2] unit is seen at 694 cm-1  in the IR spectrum of 5. In addition, an intense 
stretch at 515 cm-1 is ascribed to a vibration associated with the Ru-N coordination 
bonds of 5. Furthermore, the ν(C-N) amine observed at 1240cm-1 in the free ligand’s IR 
spectrum (Hbzpy) shifted to a lower frequency of 1227 cm-1 in the IR spectrum of 5 






The 1H NMR spectrum of 5 shows signals of the triphenylphosphine co-ligands 
emerging as two separate multiplets (7.42 – 7.35 ppm and 7.28 – 7.20 ppm) (see Figure 
4.18). Confirmation of coordination is clearly observed by a shift in the –CH2 protons for 
the free ligand at 4.61 ppm compared to 4.06 ppm as seen in 5.  In the 31P NMR 
spectrum, a single peak observed at 28.92 ppm confirms the presence of the 
phosphorous atoms in 5 indicating magnetic equivalence of these atoms (see Figure 
4.19). Broad Metal-to-Ligand Charge Transfer (MLCT) band appears for complex 5 at 
582 nm.No d-d transition is found for the diamagnetic complex, which is due to its low-
spin d6 electron configuration (see Figure 4.20). The deductions from the spectral 
characterization implies that the proposed structure of 5 is comprised of a trans-
[Ru(PPh3)2] core with the equatorial plane being occupied by the neutral bidentate 
NbzNpy chelator and the cis-orientated chloro co-ligands (see Figure 4.21).  
 








Figure 4.18: 1H NMR spectrum of complex 5. 
 
 























4.4.3 Electrochemistry studies 
The cyclic voltammograms (CVs) of 1, 2, 3 and 5 showed one redox couple while within 
the CV of the dinuclear compound 4, two redox couples labelled A and B can be found 
(see Figures 4.22 – 4.25). All the redox couples exhibits diffusion controlled behaviour at 
increasing scan rates (see Figure 4.26) for the overlay CVs of compound 4 at 
incrementing scan rates. Furthermore, the redox couples correspond to one electron 
redox processes indicated by their respective peak current ratios (Ipa/Ipc) which 
approach one. In addition, all these metallic compounds exhibit quasi-reversible 
behaviour indicated by their peak to peak separations which are different to the 
standard, ferrocene (90 mV at 100 mV/s), refer to Table4.1. More specifically, the redox 
couples of the metallic compounds 1- 3 exhibit slower electron transfer kinetics 
compared to compound 4’s redox couples A and B. The halfwave potential of complex 
1 is assigned to the Ru(III/IV) redox couple as it was found at a slightly lower potential 
than the paramagnetic diamido ruthenium(IV) complex, trans-P, cis-Cl-
[RuCl2(ddd)(PPh3)2] (H2ddd = 5, 6-diamino-1,3-dimethyluracil) [11]. For compounds 2, 
3 and 5, the halfwave potentials are ascribed to the Ru(II/III) redox couple as they have 
comparable redox behaviour as other ruthenium compounds reported in the literature 
[11, 19]. Similarly, the dinuclear ruthenium (III) compound 4 had analogous redox 
behaviour (redox couples A and B assigned to the Ru(II/III) and Ru(III/IV) process, 
respectively) as the paramagnetic ruthenium(III) complex, [RuCl(bsp)2(PPh3)] {Hbsp = 
N-(2-hydroxybenzylidene)-benzothiazole} [23].  Noticeably, using the more sensitive 
square wave voltammetry technique, at lower potentials relative to each redox process 
(viz.A and B), two smaller peaks are observed, see Figure 4.27. These peaks indicated by 








Figure 4.22: Overlay CVs of complexes 1 and 2 at 100 mV/s. 
 







Figure 4.24: CV of compound 4 at 100 mV/s. 
 







Figure 4.26: Overlay CVs of compound 4 at incrementing scan rates between 25 mV/s and 200 
mV/s. 
 






Table 4.1: Electrochemical parameters of the respective metal complexes at 100 mV/s. 
Compound 1 2 3 4 5 
A B  
Epa/V 0.025 -0.063 0.471 -0.241 0.384 0.691 
Epc/V 0.120 -0.146 0.280 -0.163 0.313 0.627 
E½/V 0.073 -0.105 0.376 -0.202 0.349 0.659 
ΔE/mV 95  83 191 78  71 64 
 
4.4.4 Radical Scavenging studies 
An increase of radicals within the human body can have detrimental effects on human 
health by inducing numerous diseases like cancer, arthritis, Parkinson’s or Alzheimer’s 
diseases [24-26]. Thus, there is an upsurge in discovering novel antioxidants which may 
offer higher radical scavenging capabilities than common natural antioxidants, e.g. 
vitamin C. Transition metal complexes with redox active metal centres have shown to 
exhibit optimal radical scavenging capabilities for a wide range of radicals by donating 
an electron to quench the radical specie [27, 28]. Alternatively, transition metal 
complexes with aromatic hydrocarbon ligands can also act as proton donors to 
neutralize radicals [29]. In our study, the formulated metal complexes 1-4 were 
subjected to DPPH radical scavenging activities. The IC50 values showed that all the 
metallic compounds [89.98 µM (for 1), 61.50 µM (for 2), 96.40 µM (for 3) and 66.31 µM 
(for 4)] have higher radical scavenging activities than their corresponding free-ligands 
[112.53 µM (for Hbzap), 87.87 µM (for H2bhb), negligible (for Htba) and 300 µM (for 
H2chpr)]. Despite the negligible radical scavenging activity of the free ligand, Htba, the 
presence of the two metal centres in compound 3 induced an optimal activity. In fact, 
the unpaired d-electron configurations of the ruthenium (III) metal centres promoted 






Furthermore, all the metal complexes had considerable higher radical scavenging 
capabilities that the natural antioxidant, vitamin C (IC50 value = 147 µM). The 
observations are well in agreement with other ruthenium (II) and – (III) compounds 
found within the literature [30-32]. 
 
4.4.5 Crystal structures 
4.4.5.1  Crystal structure of [RuCl(pho)(bzca)(PPh3)] (1)  
Complex 1 exhibits a distorted octahedral geometry which is imposed on by the O1-Ru-
N1 (79.5(1)˚) and O2-Ru-N2 (76.94(9)˚) bite angles which are significantly narrower than 
the ideal octahedral angle of 90˚ (see Figure 4.28). Furthermore, the crystal lattice is 
stabilized by π-π stacking (interplanar spacing of 3.405Å) between the nearly co-planar 







Figure 4.28: An ORTEP view of complex 1 showing 50 % probability displacement ellipsoids 
and the atom labelling. The hydrogen atoms and ethanol molecule of recrystallization were 







 In addition, re-enforcement is given by classical intermolecular (Cl····H26-O4 = 2.40(5) 
Å), (O4····H25A-N3A = 1.91(4) Å and O3····H24B-N1B = 2.09(3) Å) hydrogen bonding. 
Ultimately, these molecular interactions lead to columns of 1 running parallel to the [b]-
axis.Compound 1 exhibits several intermolecular hydrogen bonds leading to a two-
dimensional supramolecular structure transverse to the ac-plane (see Figure 4.29). The 
geometrical parameters for the hydrogen bonds supporting this structure are 
summarised in Table 4.2. 
 
 
Figure 4.29: [Left] Repeating unit of the two-dimensional hydrogen bond network of 1. [Right] 
Supramolecular structure of 1 viewed down the b-axis showing the network to be transverse to 











Table 4.2: Hydrogen bond lengths and bond angles for compound 1. 
Bond D-H H···A D···A D–H···A 
N1B–H24B···O3 0.84(3) 2.09(3) 2.884(3) 158(3) 
N3A–H25A···O4 0.85(4) 1.91(4) 2.706(4) 156(4) 
O4–H26···Cl 0.83(5) 2.40(5) 3.187(3) 159(4) 
 
In contrast to the nearly equidistant Ru-O bonds (Ru-O1 = 2.119(2) Å and Ru-O2 = 
2.124(2) Å), the ruthenium to monoanionic amido nitrogen bond (Ru-N1 = 1.904(2) Å) 
and neutral benzimidazole (Ru-N2 = 2.058(3) Å) nitrogen bond differs as expected. In 
addition, the Ru-N1 coordination sphere bond length is comparable to the analogous 
amido bonds of the paramagnetic ruthenium(IV) complex, trans-P, cis-Cl-
[RuCl2(ddd)(PPh3)2] [11]. The carboxylate form of the bzca chelator is confirmed based 
on the C-O bond orders which can be readily distinguished by their respective bond 
distances (C9-O3 = 1.225(3) Å and C9-O2 = 1.283(4) Å). 
 
4.4.5.2  Crystal structure of cis-Cl, trans-P-[RuII(Hbhb)Cl2(PPh3)2] (2)  
The molecular structure of 2 crystallizes out in a P-1 space group with two molecules 
occupying the triclinic unit cell. The bidentate coordination of the Hbhb chelator results 
in the formation of a constrained N1-Ru-O2 bite angle [85.71(7)˚] which pushes the 
chloro co-ligands (Cl1-Ru-Cl2 = 95.71(2)˚) more further apart from the ideal octahedral 
angle of 90˚ (see Figure 4.30). Furthermore, the influence of cyclometallation is clearly 
evident from the deviation from linearity of the trans-[Ru(PPh3)2] core (P1-Ru-P2 = 









Figure 4.30: An ORTEP view of complex 2 showing 50 % probability displacement ellipsoids 











Indicative to complex 1, complex 2 has a series of intermolecular interactions. Hydrogen 
bonding interaction exists between the phenolic hydrogen and amide nitrogen atoms 
(O3-H39····N2 = 1.74(3) Å). This interaction is accompanied by interactions of the C1-C6 
phenyl ring with the C15-C20 (3.598 Å) and C28-C33 (3.742 Å) phenyl rings. 
Subsequently, this leads to the benzoxazole moiety affording a dihedral angle of 17.58˚ 
with respect to the phenolic moiety and the molecules of 1 stacking in columns parallel 
to the [b]-axis. In addition to the weak C–H···Cl intramolecular interactions, compound 
2 is linked by weak intermolecular C–H···O interactions into a dimeric supramolecular 
structure, refer to Figure 4.31.  
 
Figure 4.31: Supramolecular dimeric structure of compound 2 viewed down the b-axis. The 
structure is supported by weak C–H···O interactions with geometrical parameters as follows: 
C18–H18 = 0.950 Å; H18···O1 = 2.489 Å; C18···O1 = 3.258(2) Å and C18–H18···O1 = 138˚. 
 
The cis-Ru-Cl coordination bonds (Ru-Cl1 = 2.3143(6) Å and Ru-Cl2 = 2.3462(6) Å) are 
different due to the difference in the trans-influences of the ketonic O2 and N1 






bond of 1 which is ascribed to the higher Lewis acid character of the metal centre of 1. 
Interestingly, within the cyclometallated RuN1C7N2C8O2 ring, the deprotonation of 
the amide nitrogen resulted in a delocalized pi-conjugated system throughout the 
N1C7N2C8O2 moiety which can evidently be affirmed by the comparable C7-N1 
(1.321(3) Å), C7-N2 (1.335(3) Å) and C8-N2 (1.343(3) Å) bond distances and the 
significant difference between the bond distances of C8-O2 (1.262(2) Å) from C14-O3 
(1.360(3) Å).  
 
The literature shows that numerous ruthenium benz(oxazole/imidazole) complexes 
with diverse structural features have been isolated. Among these complexes, is the 
mononuclear ruthenium (II) complex, trans-[RuCl2(Hbo)(PPh3)2] (Hbo = 2-
hydroxyphenylbenzoxazole) which has an identical Ru-Nbenzoxazole (2.120(2) Å) bond 
length as complex 2 (Ru-N1 = 2.120(2) Å) [33]. The Ru-Nbenzimidazole (2.058(3) Å) of 
complex 1 is comparable to the paramagnetic complex, trans-[RuIIICl(bzp)(PPh3)2] 
(Hbzp = N-(2-hydroxybenzylidene)benzimidazole) (Ru-Nbenzimidazole = 2.069(4) Å) [23]. 
Furthermore, as expected the Ru-O2 (2.124(2) Å) bond distance of 1 is shorter than the 
analogous bond distances of the ruthenium (II) complex, cis-[Ru(bzca)2(PPh3)2] (Ru-
Ocarboxylate = 2.133(4) Å and 2.117(4) Å) [34]. 
 
4.4.5.3  Crystal structure of (µ-Cl)2[RuCl(Hchpr)(PPh3)]2 (4)  
Each molecule of 4 crystallizes out in a P-1 space group along with two toluene 
molecules of recrystallization. The bridging chloro-co-ligands affords a constrained 4-
membered RuClRuCl ring with the opposing Cl1-Ru-Cl2 (84.94(2)˚) bond angles being 
equal (seeFigure 4.32). In addition, an inversion of symmetry occurs about these chloro-
co-ligands (viz. Cl1 and Cl2) and hence the geometrical parameters around each metal 






bite angle (N2-Ru1-N1 = 87.93(7)˚) induces non-linearity in the P1-Ru1-Cl2 (178.75(2)˚), 
N2-Ru1-Cl1 (170.77(5)˚) and N1-Ru1-Cl3 (175.55(5)˚) bond angles. 
 
Figure 4.32: An ORTEP view of compound 4 showing 50 % probability displacement ellipsoids 
and the atom labelling. The hydrogen atoms and toluene solvent molecules of recrystallization 






The terminal Ru-Cl bonds (2.3744(7) Å) are significantly shorter than the bridging Ru-Cl 
bonds (Ru1-Cl1, Ru2-Cl2 = 2.4967(5) Å and Ru1-Cl2, Ru2-Cl1 = 2.4283(6) Å) and this 
trend is typical for chloro-bridged dinuclear ruthenium compounds. Intermolecular 
hydrogen-bonding is observed between the terminal chloro co-ligands and the amido 
hydrogen at 2.83(2) Å.  Compound 4 exhibits a single classical intramolecular hydrogen 
bond (N1–H101···Cl2) with a relatively long D···A distance of 3.508(2) Å.  In addition to 
this, it also shows a number of weak intramolecular and intermolecular C–H···Cl 
interactions in the solid state. The intermolecular interactions link the molecules into a 
one-dimensional network (see Figure 4.33) which is co-linear with the b-axis. 
 
Figure 4.33: Repeating unit of the three-dimensional supramolecular structure of compound 4 supported 
by C–H···Cl interactions (indicated as dashed purple tubes) viewed down the c-axis. 
 
The mononuclear complex 1 and dinuclear compound 4 share the same oxidation state 
and have comparable Ru-Cl (terminal for 4) and Ru-P (2.3315(5) Å) bond lengths. The 
Ru-NSchiff base bond length of 4 (2.026(2) Å) is close to the lower limit of the 2.025(3) Å  - 






[11, 23, 35-38]. In addition, the monoanionic charge donation of the amido nitrogen 
results in a shorter Ru-Namido (1.972(2) Å) bond of 4 in comparison to its Ru-NSchiff base 
bond. The tetrahydropyran (THP) moiety adopts a chair conformation which is 
common to many transition metal complexes containing chelators incorporating the 
THP core [39-43].  
 
 






Table 4.3: Crystal data and structure refinement data. 
 1·CH3CH2OH 2 4·2(C7H8) 
Chemical formula C33H29ClN3O4PRu C50H39Cl2N2O3P2
Ru 
C80H76Cl4N4O6P2Ru2 
Formula weight 699.08 949.74 1595.33 
Temperature (K) 100(2) 296(2) 100(2) 
Crystal system Monoclinic Triclinic Triclinic 
Space group P21/n P-1 P-1 
Unit cell dimensions (Ǻ, °) a= 12.5002(6) a= 12.8703(7) a= 12.8091(5) 
 b= 19.6974(8) b= 12.8876(7) b= 12.9652(6) 
 c= 12.6428(5) c= 14.8744(8) c= 13.7695(6) 
 α =90 α =85.899(2) α =68.311(2) 
 β= 107.511(2) β = 70.720(2) β = 76.094(2) 
 γ = 90 γ = 65.173(2) γ = 82.489(2) 
Crystal size (mm) 0.29 x 0.18 x 0.03 0.21 x 0.04 x 0.02 0.60 x 0.09 x 0.04 
V(Å3) 2968.7(2) 2107.1(2) 2060.34(15) 
Z 4 2 1 
Density (calc.) (Mg/m3) 1.564 1.497 1.286 
Absorption coefficient (mm-1) 0.716 0.622 0.585 
F(000) 1424 970 818 
θ range for data collection (deg) 1.98; 26.03 1.75; 26.16 1.63; 26.11 
Index ranges -14 ≤ h ≤ 15 
-20 ≤ k < 24 
-11 ≤ ℓ ≤ 15 
-15 ≤ h ≤ 15 
-15 ≤ k < 15 
-18 ≤ ℓ ≤ 182 
-15 ≤ h ≤ 15 
-12 ≤ k < 15 
-17 ≤ ℓ ≤ 17 
Reflections measured 16731 35691 33857 
Observed reflections [I>2σ(I)] 5837 8256 7981 
Independent reflections 4698 7043 7260 
Data/Restraints/parameters 4698/0/401 7043/1/545 7260/0/447 
Goodness of fit on F2 1.028 1.026 1.045 
Observed R, wR2 0.0363, 0.0767 0.0280, 0.0603 0.0282, 0.0726  






































Table 4.6: Selected bond lengths [Å] and bond angles [°] for 4. 
Ru-Clterminal 2.3744(7) 
Ru1-Cl1 2.4967(5) 
Ru2-Cl2   2.4967(5) 
Ru1-Cl2 2.4283(6) 
Ru2-Cl1   2.4283(6) 
Ru-P 2.3315(5) 
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Coordination modes of Di- and Triimines towards 
Ruthenium(II) and -(III) centres: Structural, 
Electrochemical and Radical Scavenging studies 
 
5.1 Introduction 
The discovery of NAMI-A, trans-[RuIIICl4(DMSO)(Im)](ImH) (ImH = protonated 
imidazole)as a potential ruthenium metallopharmaceutical has led to a resurgence of 
interest in the coordination chemistry of ruthenium in medicinal inorganic chemistry [1-4]. 
Meticulous ligand design by utilizing chelators with neutral nitrogen donor atoms (e.g. 
[Ru(bpy)3]2+) has proven favourable in the stabilization of ruthenium in both high and low 
oxidation states [4-6]. In addition, the high metal-binding affinity of this class of ligands 
makes them excellent candidates as bifunctional chelators of ruthenium centres and 
scaffolds incorporating biologically relevant moieties [7-8]. The inclusion of biologically 
relevant ligands in coordination compounds of ruthenium is geared towards improving the 
biodistribution patterns of the metal complexes, thereby potentially minimizing side-effects 
with respect to healthy cells [9-10]. Literature have shown the exploration of coordination 
susceptibility of Schiff bases derived from biologically relevant moieties towards the 
ruthenium(II) and –(III) cores [11-14].  
 
Like in the case of the coordination reactions of trans-[RuCl2(PPh3)3] with the diimine 
ligands 2,6-bis-((6-amino-1,3-dimethyluracilimino)methylene)pyridine (H4ucp) and 2,6-bis-
((antipyrine-imino)methylene)pyridine (bpap) which readily afforded the metal complexes, 
[RuII(H3ucp)Cl(PPh3)] and cis-[RuIICl2(bpap)(PPh3)], respectively [11]. The dinuclear 
ruthenium compound, (µ-Cl)2[RuIIICl(Hchpr)(PPh3)]2 (H2chpr = 2-amino-3-((tetrahydro-2H-
pyran-4-ylimino)methyl)-4H-chromen-4-one) exhibits optimal redox properties governed 






voltammogram. In turn, these optimal redox properties induced significantly higher DPPH 
radical scavenging activity than the corresponding free-ligand, H2chpr and the natural 
antioxidant, vitamin C [13]. 
 
In this chapter, we investigate the coordination modes of di- and triimines towards the 
ruthenium(II) and –(III) cores. More specifically, the diamagnetic ruthenium(II) complex, 
cis-[RuCl2(thppy)(PPh3)] (1), the paramagnetic ruthenium(III) compounds, (µ-chb)[mer-
RuCl3(PPh3)]2 (2) and [Ru(pym)] (3) were isolated from the 1:1 molar coordination reactions 
of trans-[RuIICl2(PPh3)3] with 2,6-bis-((tetrahydropyranimino)methyl)pyridine (thppy), 
N1,N2-bis((chromone)methylene)benzene-1,2-diamine (chb) and tris-((1H-pyrrol-2-
ylmethylene)ethane)amine (H3pym), respectively. To evaluate the antioxidant potential of 
ruthenium compounds, radical scavenging studies were conducted with the DPPH and NO 
radicals. Notably, the biologically significant components of the present compounds (viz. 
pyrrole, chromone and tetrahydropyran) and their derivatives are known to exhibit both 
antioxidant and anticancer activities [13, 15, 16]; hence the inclusion of these moieties in 
metal complexes could potentially promote target-specific in vivo biodistribution patterns 













5.2.1 Synthesis of ligands: 
5.2.1.1  2,6-bis-((4-tetrahydropyranimino)methyl)pyridine (thppy) 
A reaction mixture of 2,6-pyridinedicarboxaldehyde (0.20 g; 1.48 mmol), tetrahydro-2H-
pyran-4-amine (0.31 cm3; 2.96 mmol) and a catalyst, piperidine (3 drops) was heated at 
reflux temperature in methanol (20 cm3). After four hrs, the resultant solution was left to 
stand for two days at room temperature. Then a cream white precipitate was filtered and 
washed with petroleum ether. M.P. = 133 – 135 ˚C; Yield = 92 %; IR (νmax/cm-1): υ(C=N) 
1643 (s), υ(O-C-O)thp 1134, 1081 (vs);1H NMR (295K/ppm): 8.44 (s, 2H, H6, H12), 8.03–7.92 
(m, 3H, H8, H9, H10), 3.99–3.89 (m, 4H, H5, H5́, H18, H18́), 3.84–3.75 (m, 2H, H1, H13), 
3.68–3.57 (m, 2H, H1́, H13́),  3.52–3.89 (m, 4H, H4, H4́, H17, H17́), 2.77–2.63 (m, 2H, 
H2, H14), 1.45–1.29 (m, 2H, H2́, H14́), 1.27–1.13 (m, 2H, H3, H16); UV-vis (DCM, (λmax (ε, 
M-1cm-1))): 254 nm (8232); 278 nm (sh, 6137); 291 nm (7090); 298 nm (sh, 5259). 
 







5.2.1.2  N1,N2-bis((3-chromone)methylene)benzene-1,2-diamine (chb) 
3-Formylchromone (0.50 g; 2.88 mmol) and 1,2-diaminobenzene (0.15 g; 1.44 mmol) were 
heated at reflux temperature for five hrs in dry toluene.  The reaction mixture was allowed 
to cool to room temperature and a red precipitate formed which was filtered and washed 
with cold toluene as well as petroleum ether. M.P. = 238 – 240 ˚C; Yield=90 %; IR (νmax/cm-
1): υ(C=O) 1633 (s), υ(C=N) 1635 (sh, m),υ(O-C-O)thp 1131 (br, vs); 1H NMR (295K/ppm): 
14.27 (br, s, 2H, H6, H23); 10.19 (br, s, 2H, H10, H17); 8.56 (d, 2H, H1, H18); 7.41 – 7.29 (m, 
4H, H3, H12, H15, H20); 7.21 – 7.13 (m, 4H, H2, H13, H14, H19); 7.00 – 6.91 (m, 2H, H4, H21); 











5.2.1.3  Tris-((1H-pyrrol-2-ylmethylene)ethane)amine (H3pym) 
This compound was prepared using a method similar to those previously reported [17]. To 
a solution of tris-(2-aminoethyl) amine (1 cm3; 6.84 mmol) in absolute ethanol (20 cm3), 
pyrrole-2-carboxaldehyde (1.95 g; 20.52 mmol) was added with constant stirring. The 
resulting reaction mixture was heated until reflux for three hrs and cooled. Orange red 
crystalline material was obtained from the slow evaporation of ethanol/acetonitrile mixture 
(1:1, v/v). M.P = 138 – 140 ˚C; Yield= 80 %; IR (νmax/cm-1): υ(N-H) 3122, 3061 (m), υ(C=N)imine 
1644 (vs), υ(C=N)heterocyclic 1555 (sh, m);1H NMR (295K/ppm): 11.30 (br, s, 3H, NH), 7.97 (s, 
3H, H5, H12, H19), 7.99 – 7.93 (m, 3H, H3, H10, H17), 6.35 – 6.32 (m, 3H, H1, H8, H15), 6.08 
(t, 3H, H2, H9, H16), 3.33 (br, s, 12H, H6, H6́, H7, H7́, H13, H13́, H14, H14́, H20, H20́, H21, 
H21́). UV-vis (DCM/CH3CN, (λmax (ε, M-1cm-1))): 283 nm (46720); 346 nm (1423). 
 
 






5.2.2 Synthesis of metal complexes 
5.2.2.1  cis-[RuCl2(thppy)(PPh3)] (1) 
A 1:1 molar reaction mixture of thppy (0.0314 g; 104 µmol) and trans-[RuCl2(PPh3)3] (0.100 
g; 104 µmol) was heated under reflux in toluene (20 cm3) for six hrs. From the resulting 
dark purple solution, a maroon precipitate was attained. This precipitate was dissolved in 
dichloromethane and layered with hexane. XRD quality dark crystals were obtained from 
the layered solution after several days. M.P. > 350˚C; Yield = 80% (based on Ru);IR 
(νmax/cm-1): υ(C=N) 1635 (w), υ(O-C-O)thp 1134, 1081 (vs), υ(Ru-PPh3) 698, υ(Ru-N) 525;1H 
NMR (295K/ppm): 8.28 (s, 2H, H6, H12), 7.70 – 7.12 (m, 18H, H8, H9, H10, PPh3), 4.34 (t, 2H, 
H5, H18), 3.95 – 3.86 (m, 2H, H5́, H18́), 3.80 – 3.71 (m, 2H, H1, H13), 3.15 (t, 2H, H1́, 
H13́), 2.72 (t, 2H, H4, H17), 2.40 – 2.19 (m, 2H, H4́, H17́), 1.99 – 1.74 (m, 2H, H2, H14), 
1.31 – 1.21 (m, 2H, H2́, H14́), 0.61 (d, 2H, H3, H16); 31P NMR (295K/ppm): 
30.58;Conductivity (DCM, 10-3M): 12.5 ohm.cm2.mol-1; UV-vis (DCM, λmax (ε, M-1 cm-1)): 239 
nm (52195); 297 nm (sh, 6644); 317 nm (sh, 5137); 332 nm (sh, 3356); 461 nm (5848); 571 nm 
(2522); 688 nm (sh, 469). 
 
5.2.2.2  cis-Cl, (µ-chb)[RuCl3(PPh3)]2 (2) 
A mixture of chb (0.0276 g; 104 µmol) and trans-[RuCl2(PPh3)3] (0.100 g; 104 µmol) in 
toluene (20 cm3) and one drop of 32% hydrochloric acid was heated under reflux for six hrs. 
A dark brown precipitate was filtered and washed with toluene as well as diethyl ether. 
Upon addition of 10 cm3 acetonitrile to the filtrate, the slow evaporation of the resultant 
mixture afforded brown crystals suitable for X-ray analysis. M.P. > 350˚C; Yield = 77% 
(based on Ru); IR (νmax/cm-1): υ(N-H) 2950, 2938, 2846 (m), υ(C=N)imine 1615 (s), υ(O-C-O) 
1159, 1143 (m), υ(Ru-PPh3) 692 (vs), υ(Ru-N) 526 (vs),  υ(Ru-O) 455 (w); Conductivity (DCM, 
10-3 M): 12.66 ohm.cm2.mol-1; UV-vis (DCM, λmax (ε, M-1 cm-1)): 263 nm (sh, 19164); 360 nm 
(13173); 454 nm (sh, 8522); 723 nm (sh, 1465). 
 
5.2.2.3  [Ru(pym)] (3)  
Equimolar quantities of H3pym (0.0394 g; 104 µmol) and trans-[RuCl2(PPh3)3] (0.100 g; 0.104 






precipitate was filtered and washed with toluene, MeOH, CH3CN, DCM and diethyl ether. 
Slow evaporation of the filtrate gave dark brown crystals. M.P. > 350˚C; Yield = 91% (based 
on Ru); IR (νmax/cm-1): υ(C=N)imine 1605 (sh, s), υ(C=N)heterocyclic 1573 (vs), υ(Ru-N) 524, 513 
(vs);Conductivity (DMSO/CH3CN (1:1, v:v), 10-3 M): 16.95 ohm.cm2.mol-1; UV-vis 
(DMSO/CH3CN, λmax (ε, M-1 cm-1)): 291 nm (17531); 361 nm (sh, 10891). 
 
5.3 X-ray diffraction 
The X-ray data for the metal complexes were recorded on a Bruker Apex Duo 
equippedwith an Oxford Instruments Cryojet operating at 100(2) K and an Incoatec 
microsource operating at 30W power. Crystal and structure refinement data are given in 
Table 5.2. Selected bond lengths and angles are given in Tables 5.3, 5.4 and 5.5 for 1.H2O, 
2.CH3CN and 3, respectively. In all three cases the data were collected with Mo Kα (λ = 
0.71073 Å) radiation at a crystal-to-detector distance of 50 mm. The following conditions 
were used for data collection: omega and phi scans with exposures taken at 30 W X-ray 
power and 0.50º frame widths using APEX2 [18]. The data were reduced with the program 
SAINT [18] using outlier rejection, scan speed scaling, as well as standard Lorentz and 
polarization correction factors. A SADABS semi-empirical multi-scan absorption correction 
[19] was applied to the data. Direct methods, SHELX-2014 [20] and WinGX [21] were used 
to solve all three structures. All non-hydrogen atoms were located in the difference density 
map and refined anisotropically with SHELX-2014 [20]. All hydrogen atoms were included 
as idealised contributors in the least squares process. Their positions were calculated using 
a standard riding model with C-Haromatic distances of 0.93 Å and Uiso = 1.2 Ueq, C-Hmethylene 
distances of 0.99 Å and Uiso = 1.2 Ueq and C–Hmethyldistances of 0.98 Å and Uiso = 1.5 Ueq.  The 
O-H bonds of the water molecule for 1 were located in the difference density map and 











5.4 Results and Discussion 
5.4.1 Synthesis and spectral characterization 
The isolated ruthenium compounds 1 - 3 were formulated from the equimolar coordination 
reactions of trans-[RuCl2(PPh3)3] with the respective Schiff bases: thppy, chb and H3pym. In 
1, the thppy moiety acts as a neutral tridentate chelator through its (NN)iminoNpy donor set 
while for 2, the neutral chb moiety bridges the two cis-[RuIIICl3] cores via its ketonic oxygen 
and imino nitrogen atoms. In the formation of the dinuclear compound 2, initially the 
hydrochloric acid dissociates into its constituent ions followed by the oxidation of the metal 
centres by H+ cations and in the process diatomic hydrogen gas forms from the reaction 
mixture [22, 23]. Lastly, the coordination of chloro anions and the chelator to the respective 
metal atoms resulted in the isolation of 2.  Interestingly, the triimine pym chelator displaced 
all the co-ligands of the metal precursor leading to octahedral saturation through its three 
imino nitrogens and three deprotonated pyrrolidine nitrogen atoms. In fact, this 
phenomenon has been observed in the coordination reactions of trans-[RuCl2(PPh3)3] with  
analogous tripodal triimine ligands derived from tris-(2-aminoethyl)amine [24]. However, 
the rigid ruthenium(II) arene cores remained intact for the organometallic ruthenium(II) 
complexes, [Ru(Ar)Cl(sal3tr)] (sal3tr = tris-2-(salicylaldimine ethyl)amine) and 
[Ru(Ar)Cl(py3tr)] (py3tr = tris-2-(2-pyridylimine ethyl)amine) where the arene (Ar) core can 
be hexamethylbenzene, para-cymene or hydroxyethoxybenzene [25]. 
 
Compounds 1 and 2 are highly soluble in high boiling point aprotic and chlorinated 
solvents while complex 3 is only partially soluble in a 1:1 (v:v) mixture of 
dimethylsulphoxide and acetonitrile. The low molar conductivity values of the formulated 
metal complexes affirm that they are non-electrolytes [11, 26]. Only low resolution EPR 
spectra could be obtained for the metal complexes 2 and 3 which are typical of 
ruthenium(III) complexes with distorted octahedral geometries[27, 28], see Figure 5.5. The 
1H NMR spectrum of 1 shows that the imino protons appear as a sharp singlet (at 8.28 
ppm) which is more downfield in comparison to the analogous signal of its free ligand, 






integrates to 18 protons ascribed to the pyridyl moiety and triphenylphosphine co-ligand. 
The uncoordinated tetrahydropyran (thp) moieties are characterized by the expected up-
field multiplet signals in the NMR spectrum between 3 and 4 ppm. Both thp moieties 
exhibit chair conformations in solution as evidenced by the lack of signals from boat 
conformers of the 6-membered rings (this is consistent with the X-ray data for 1, vide infra). 
As expected, only one signal is observed in the 31P NMR spectrum of 1 due to 
itstriphenylphosphine co-ligand, see Figure 5.7. 
 








Figure 5.6: 1H NMR spectrum of complex 1. 
 






The IR spectra of the free ligands contain strong vibrations that are readily assigned to the 
imine C=N groups at 1643 cm-1 (for thppy), 1635 cm-1 (for chb) and 1644 cm-1 (for H3pym), 
see Figures 5.8–5.10. Noticeably, these vibrations are found at significantly lower 
frequencies in the IR spectra of the respective metal complexes, viz. 1635 cm-1 for 1, 1615 cm-
1 for 2 and 1605 cm-1 for 3, consistent with metal-to-ligand back-donation of electron density 
into * molecular orbitals involving the C=N groups, which partly reduces the C=N bond 
order and thus stretching frequency of the C=N group relative to the free ligand. The 
intense stretching modes of the Ru–P bonds, υ(Ru-PPh3) for 1 and 2 are found at 698 cm-1 
and 692 cm-1, respectively. Interestingly in 1, the C–O–C ether group vibrations of the 
uncoordinated thp moieties vibrate at identical frequencies to those of the free ligand, 
thppy [ν(O-C-O) = 1081 cm-1 and 1134 cm-1]. This reflects the fact that no interaction 
between the thp groups and metal atom exists. In contrast for 2, the broad C–O–C ether 
group vibration (1131 cm-1) of the free ligand, chb appears as a medium-intensity split 
vibration [at 1159 cm-1 and 1143 cm-1] in the IR spectrum of the metal complex. The absence 
of the pyrrole N-H vibrations in the IR spectrum of 3 reflects deprotonation of the pyrrole 
rings and their coordination to the ruthenium(III) centre. For the remaining coordination 
sphere bonds, the Ru-N vibrational modes of the metal complexes are comparable with one 







Figure 5.8: Overlay IR spectra of complex 1 and its free-ligand, thppy. 
 







Figure 5.10: Overlay IR spectra of complex 3 and its free-ligand, H3pym. 
 
The UV-Vis spectral analysis reveals that several common intraligand π-π* electronic 
transitions are shared among the free ligands and their respective metal complexes, see 
Figures 5.11–5.13. Furthermore, metal-to-ligand charge transfer (MLCT) bands at 461 nm 
and 571 nm for 1 are observed and despite its d6 low-spin electron configuration, a metal-
based (at 688 nm) electronic transition with a low extinction coefficient is observed. 
However, for the paramagnetic ruthenium(III) compounds, only a weak d-d transition for 2 
is observed at 723 nm. The absence of the metal-based electronic transition of 3 is ascribed 
to a higher band-gap energy, whereas in 1, a narrow band-gap energy makes the d-d 










Figure 5.11: Overlay UV-Vis spectra of complex 1 and its free-ligand, thppy. 
 







Figure 5.13: Overlay UV-Vis spectra of complex 3 and its free-ligand, H3pym. 
 
5.4.2 Voltammetry Analysis 
Firstly, the voltammetric analysis of 3 was conducted in a 1:1 (v:v) solvent mixture of 
DMSO and CH3CN since this complex is insoluble in DCM. Noteworthy for 3, the use of 
coordinative solvents can potentially influence the redox behaviour of 3 as solvents such as 
DMF and DMSO typically induces axial coordination of metallophthalocyanines and in the 
process renders metal-based redox processes during voltammetry analysis [30]. The redox 
behaviours of 1 and 2 in the non-coordinating solvent, DCM shows one and two redox 
couples in their cyclic voltammograms (CVs), respectively (see Figures 5.14 and 5.15). All 
these redox couples are quasi-reversible as their peak-to-peak separations (ΔE) are different 
[ΔE(1) = 150 mV, ΔE(2-A) = 81 mV  and ΔE(2-B) = 80 mV] to that of the ferrocene standard 
[ΔE(ferrocene-DCM) = 90 mV vs Ag|AgCl] under the same experimental conditions. The 
redox couples exhibits diffusion-controlled behaviour at increasing scan rates and have 






a one electron redox process. The single quasi-reversible redox couples observed in the CVs 
of 1 and 3 [ΔE(3) =  110 mV against the ΔE(ferrocene-mixture)= 100 mV] are consistent with 
the Ru(II/III) redox process as the halfwave potentials [E½(1) = 0.625 V and E½(3) = -0.755 V 
vs Ag|AgCl] compare favourably with other ruthenium(II) and –(III) complexes where the 
voltammetric studies have been conducted in either coordinating or non-coordinating 
solvents [11, 29, 31]. Compound 2 mimics the redox behaviour of the dinuclear (µ-
Cl)2[RuIIICl(Hchpr)(PPh3)]2 (H2chpr = 2-amino-3-((tetrahydro-2H-pyran-4-ylimino)methyl)-
4H-chromen-4-one) with the Ru(II/III) [E½ = -0.143 V vs Ag|AgCl] and Ru(III/IV) [E½ = 




Figure 5.14: Cyclic voltammograms (CVs) of 1 and 3 as well as their corresponding ferrocence 
standards at a scan rate of 100 mV/s conducted in DCM (viz. Ferrocene-DCM) and the 
















5.4.3 Radical Scavenging Studies 
Abnormally high concentrations of free radicals in the human body are associated with 
oxidative stress and nitrosamination processes which can potentially lead to an array of 
cancers, Alzheimer’s disease and cardiovascular ailments [32-34]. Current trends entail 
exploring the radical scavenging capabilities of ruthenium compounds as an alternative to 
the natural antioxidant, vitamin C and organic-based synthetic radical scavengers (e.g. 
butylated hydroxyl toluene (BHT)). The attractive attribute of these metal-based 
compounds is the easily interconverted oxidation states of ruthenium which makes them 
effective scavengers of free radicals. More specifically, the radical scavenging capabilities of 
ruthenium complexes can be induced either by the donation of an electron or a hydrogen 
from hydrocarbon co-ligands of the ruthenium complexes [35-37]. Furthermore, as the 
biologically significant components (viz. tetrahydropyran in 1, chromone in 2 and pyrrole 
in 3) are known antioxidants, the presence of these moeities can potentially enhance the 
radical scavenging capabilities of the formulated metallic compounds 1 - 3.  
 
The influence of the redox active metal centre is clearly noted with an increase in the radical 
scavenging activity of the metal complexes in comparison to the free ligand. Most notabaly 
is the NO radical scavenging activity of compound 2 [IC50(NO) = 143 µM] versus thppy 
[IC50(NO) = 308 µM], refer to Table 5.1. Furthermore, predominately all the metal 
complexes have lower IC50 values than the natural antioxidant, vitamin C [IC50(NO) = 210 
µM and IC50(DPPH) = 147 µM], with the exception of 1 (for NO) and 3 (for DPPH) [38, 39]. 
As mentioned before, the dinuclear compound, (µ-Cl)2[RuIIICl(Hchpr)(PPh3)]2 exhibits 
similar redox behaviour as metal complex 2 and their resemblance is also reflected in their 
similar radical scavenging capabilities towards the DPPH radical [13]. In addition, the 
chromone-derived Schiff base neutralizes the NO and DPPH radicals more effectively 
compared with vitamin C while the thppy free-ligand has comparable DPPH radical 









Table 5.1: IC50 values (in µM) of the metal complexes and their free-ligands. Each IC50 value has a 








5.4.4 Crystallographic studies 
Complex 1 co-crystallizes with a water molecule of recrystallization in the space group 
P21/n. Each monoclinic unit cell contains four molecules of 1·H2O and the crystal lattice is 
stabilized by a network of hydrogen-bonding occurring between 1·H2O dimers in which 
the water molecules bridge the complexes by hydrogen bonds involving the coordinated 
chloride ions, see Figure 5.16. Within each dimer, these hydrogen-bonding interactions 
induce the formation of an intermolecular 4-membered ring [Cl2···H1S-O3/ Cl2A···H1SA-
O3A = 2.25(3) Å and Cl2A···H2S-O3/ Cl2···H2SA-O3A = 2.30(3) Å]. Furthermore, an 
intramolecular ringring -type interaction occurs between the nearly co-planar pyridyl 
moiety and the C19-C24 phenyl ring of the PPh3 co-ligand (centroidcentroid distance, 
3.511 Å, see Figure 5.17).  
 NO DPPH 
1 231  44  
2 143  87  
3 151  194  
thppy 527  54  
chb 199  118  







Figure 5.16: A perspective view of the dimer of 1.H2O formed by a series of hydrogen bonding 
interactions: Cl2···H1S-O3 (W)/ Cl2A···H1SA-O3A (Y) = 2.25(3) Å and Cl2A···H2S-O3 (X)/ 
Cl2···H2SA-O3A (Z) = 2.30(3) Å. 
 
Figure 5.17: A perspective view of 1 showing the nearly co-planar pyridyl moiety and the C19-C24 






The crystal lattice of 2 is made up of concentric columns of 2 which run parallel both to the 
[a]- and [b]-axes. This arrangement of the molecules is conferred via intermolecular 
interactions between co-planar phenyl rings of the PPh3 co-ligands and the annealed phenyl 
rings of the chromone with a distance of 3.798 Å, see Figure 5.18. An example is the 
interaction of the C45-C50 phenyl ring of the P(2)Ph3 of 2 with respect to the C1-C5C9 ring 
of a chromone moiety of an adjacent molecule and the interaction between the C27-C32 
phenyl ring of the triphenylphosphine co-ligand and the C18-C22C26 ring of the chromone 
moiety of a neighbouring molecule. The larger unit cell dimension of 3 allows sixteen 
molecules of 3 to pack in its cubic unit cell. 
 
 
Figure 5.18: A perspective view of 2 along the [a] and [b] axes illustrating the intramolecular 






Although the bridging phenyl moiety (of the chb chelator in 2) lies out of the planes of the 
chromone moieties by 88.20˚ and these moieties also form a dihedral angle of 65.31˚, the 
geometrical parameters around each metal centre in 2 are identical. Thus, the bond angles 
around the Ru1 atom will only be discussed. The octahedral coordination sphere of the 
metallic compounds are distorted as evidenced by the non-perpendicular bite angles [N1-
Ru-N2 = 78.71(6)˚ and N2-Ru-N3 = 78.73(6)˚ for 1, O1-Ru1-N1 = 89.5(1)˚ for 2 and Npyrrole-
Ru-Nimino = 77.94(8)˚ and Nimino-Ru-Nimino = 100.32(9)˚ for 3] (see Figures 5.19 – 5.21). This 
deviation from octahedral coordination is emphasized further by the deviation from 
linearity of the equatorial bond angles for 1 [N2-Ru-Cl2 = 170.09(4)˚ and N1-Ru-N3 = 
157.42(6)˚], the  axial bond angle for 2 [Cl2-Ru1-Cl3 = 167.60(5)˚] as well as the Npyrrole-Ru-
Nimino bond angles of 172.37(9)˚ for 3. 
 
 Surprisingly in 1,the Ru-Nimino bond distances [Ru-N1 = 2.061(2) Å and Ru-N3 = 2.090(2) Å] 
are not equidistant; this is accompanied by commensurate differences for the opposing 
C=N-C bond angles [C6-N1-C3 = 121.2(1)˚ and C12-N3-C16 = 118.5(1)˚]. The anomalies in 
the above geometrical parameters probably reflect minor differences in the positions of the 
thppy moieties in three dimensional space. The Ru-Nimino bond length is considerably 
longer in the paramagnetic ruthenium compound 2 [Ru-Nimino =2.159(4) Å] due to their 
higher Lewis acid character of its metal atom compared to the diamagnetic character of 1. 
As expected, the same trend is found when comparing the Ru-P [2.3099(5) Å for 1 and Ru1-
P1 = 2.330(1) Å for 2] and Ru-Cl [Ru-Cl1 = 2.4324(5) Å and Ru-Cl2 = 2.4707(5) Å for 1; Ru1-
Cl1 = 2.324(1) Å, Ru1-Cl2 = 2.332(1) Å and Ru1-Cl3 = 2.355(1) Å for 2] coordination sphere 
bonds.The variable trans-influences of the N2 and P atoms effective on the chloro co-
ligands accounts for the differences in the Ru-Cl bond distances of 1 whereasthe 
meridonally-arranged chloro co-ligands in 2 have comparable bond lengths to other 
metallic compounds containing the mer-[RuCl3]3+ core [40-42].However in 3, due to the 
presence of the non-delocalized bridging aliphatic amine moiety, its Ru-Nimino bond 
distances of 2.070(2) Å are shorter than those of 2. Also, the identical Ru-Npyrrole [2.049(2) Å] 
bond lengths of 3 were in the range [2.037(6)-2.082(9) Å] found for other ruthenium to 







The bond orders of the carbonyl-like C8-O1/C25-O3 double bonds of 2 are clearly 
established based on their shorter bond distances [1.251(5) Å] in comparison with the ether-
type C–O bonds [O2-C6/O4-C23 = 1.333(7) Å and O2-C5/O4-C22 = 1.373(6) Å]; in effect, 
these bonds are in their ketonic forms. In support of the aforementioned deduction, the Ru-
Oketonic bond distance [2.083(3) Å] differs clearly from the literature-based RuIII-Ophenolatebond 
distances as seenin trans-[Ru(L)Cl(PPh3)2] [1.9906(15) Å]  (H2L = 2-hydroxy-1-
naphthaldehyde-benzoylhydrazone), [Ru(pyhz)2]ClO4 [1.971(2)Å]  (Hpyhz = 2-((2-(pyridin-
2-yl)hydrazono)methyl)phenol) and [Ru(pzpo)(acac)] (H2pzpo = 1,2-bis(2-(1-methyl-1H-




Figure 5.19: An ORTEP view of complex 1 showing 50 % probability displacement ellipsoids and 









Figure 5.20: An ORTEP view of compound 2 showing 50 % probability displacement ellipsoids and 











Figure 5.21: An ORTEP view of complex 3 showing 50 % probability displacement ellipsoids and 






Table 5.2: Crystal data and structure refinement data. 
 1.H2O 2.CH3CN 3 
Chemical formula C35H40Cl2N3O3PRu C66H52Cl6N4O4P2Ru2 C21H24N7Ru 
Formula weight 753.64 1441.92 475.54 
Temperature (K) 100(2) 100(2) 100(2) 
Crystal system Monoclinic Orthorhombic Cubic 
Space group P21/n P21212 I-43d 
Unit cell dimensions (Ǻ, °) a = 15.1098(5) a = 16.168(1) a = 19.9699(7) 
 b = 13.5262(5) b = 20.6678(13) b = 19.9699(7) 
 c = 16.6804(6) c = 9.2012(6) c = 19.9699(7) 
 α = 90 α = 90 α = 90 
 β = 97.080(2) β = 90 β = 90 
 γ = 90 γ = 90 γ = 90 
V(Å3) 3383.1(2) 3074.6(3) 7963.9(8) 
Z 4 2 16 
Density (calc.) (Mg/m3) 1.480 1.577 1.586 
Absorption coefficient (mm-1) 0.708 0.857 0.810 
F(000) 1522 1456 3888 
θ range for data collection 
(deg) 
1.7; 27.1 1.60; 26.00 2.50; 30.01 
Reflections measured 22561 11872 13549 
Observed reflections [I>2σ(I)] 6565 5479 1804 
Independent reflections 7443 5863 1913 
Data/Restraints/parameters 7443/2/414 5863/1/384 1913/0/88 
Goodness of fit on F2 1.022 1.091 1.061 
Observed R, wR2 0.025; 0.060 0.031; 0.076 0.024; 0.0487 
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The isolation of new Ruthenium complexes with 
Lumazine derivatives: Structural, Electrochemical, 
Computational and Radical Scavenging Studies 
6.1 Introduction 
The exploration of ruthenium in medicinal inorganic chemistry is largely due to the 
discovery of NAMI-A, trans-[RuCl4(DMSO)(Im)](ImH) {ImH = protonated imidazole} 
and KP1019 (trans-tetrachlorobis(indazole)ruthenate(III)) as potential metal-based 
anticancer drugs [1, 2]. Their high cytoxicity towards metastatic tumours are accounted 
to the fact that ruthenium is a group congener of the essential element, iron and these 
first generation ruthenium chemotheraputic drugs share similar biodistribution 
patterns as iron [3, 4]. However, more innovative drug design strategies are required to 
negate the common side effects associated with chemotherapy [5].  
 
A current design strategy entails the use of scaffolds encompassing biologically 
significant moeities within the coordination sphere of ruthenium complexes [6]. These 
biologically significant moeities may promote the physiological biocompatability of the 
ruthenium complex and can also facilitate a target specific biodistribution towards 
tumours [7].  Hence the design of new target-specific ruthenium chemotherapeutic 
drugs provides scope for exploring the fundamental coordination chemistry of 
ruthenium towards biologically relevant ligand systems.  
 
A plausible candidate as a biologically active moeity is lumazine which is a derivative 
of the enzyme, Lumazine synthase [8]. Lumazine synthase plays a pivotal role in the 






riboflavin has been found to be associated with high tendencies of breast and cervical 
cancer occurences [10]. Moreover, one of the annealed ring systems of lumazine is a 
uracil which is a constituent of well-established chemotherapeutic drugs, uramustine 
and 5-fluoro-uracil [11]. In fact, demonstration of the coordination susceptibility of 
Schiff bases derived from 5, 6-diamino-1, 3-dimethyluracil towards ruthenium have 
been reported recently [12, 13].  
 
In this chapter, the isolation of new ruthenium complexes containing ligands derived 
from 6-acetyl-1,3,7-trimethyllumazine (almz) are reported. The coordination reactions 
using trans-[RuCl2(PPh3)3] as the metal precursor yielded the diamagnetic ruthenium(II) 
complex, cis-[RuCl2(bzlmz)(PPh3)] (1) and paramagnetic ruthenium(III) complexes, cis-
[RuCl2(olmz)(PPh3)] (2). The resultant metal complexes were spectroscopically 
characterized and structurally elucidated with single crystal X-ray analysis. In 
addition,the potentialantioxidant capabilities of these metal complexes were evaluated 

































6.2.1 Synthesis of ligands: 
6.2.1.1  6-acetyl-1,3,7-trimethyllumazine (almz) 
The titled pro-ligandwas obtained from the reaction of 6-amino-1,3-dimethyl-5-
nitrosouracil with acetylacetone as adapted from an experimental procedure attained 
from the  literature [14]. 
 
6.2.1.2             N-1-[1,3,7-trimethyllumazine]benzohydride (bzlmz) 
The synthetic procedure of the title compound was adopted and modified from a 
method previously reported [15]. The condensation reaction of benzohydrazide (0.11 g; 
0.81 mmol) and 6-acetyl-1,3,7-trimethyllumazine(almz) (0.20 g; 0.81 mmol) was 
conducted in ethanol (20 cm3). The resultant reaction mixture was heated until reflux 
for 6 hrs in the presence of a few drops of glacial acetic acid. A pale yellow solid formed 
which was filtered and washed with diethyl ether. Yield = 78%; M.P. = 258 - 260˚C; IR 
(νmax/cm-1):  ν(N-H)amide3226 (w), υ(C=O)lumazine 1694 (br, s), υ(C=O)amide 1652 (br, s), 
υ(C=N)lumazine 1547 (m), ν(C-N)amide1268 (m);  1H NMR (295K/ppm): 11.00 (s, 1H, N6-H), 
9.36 (br, s, 2H, H14, H18), 7.72 – 7.40 (m, 3H, H15, H16, H17), 3.57 (s, 3H, C8-H3), 2.82 (s, 
3H, N1-CH3), 2.65  (s, 3H, N2-CH3),2.09 (s, 3H, C11-H3); UV-Vis (DCM, (λmax (ε, M-1cm-









Figure 6.2: 1H NMR spectrum of the free-ligand bzlmz in the region of 7.21 and 11.52 ppm. 
 
6.2.1.3  6-(hydroxyimino)ethyl)-1,3,7-trimethyllumazine (ohlmz) 
The reaction of hydroxylamine hydrochloride (0.07 g; 1.01 mmol) and 6-acetyl-1, 3, 7-
trimethyllumazine(almz)  (0.20 g; 0.81 mmol) was carried out in 20 cm3 of ethanol  
under reflux for 6 hrs in the presence of a few drops of glacial acetic acid from a method 
previously reported [16]. Slow evaporation of the solution gave a pale purple crystalline 
material. Yield = 81%; M.P. = 240 - 242˚C; IR (νmax/cm-1): ν(N-H) 3440 (m), ν(O-H) 2901 
(br, m), ν(C=O)lumazine 1707 (s), 1648 (vs, sh), ν(C=O)amide 1640 (br, s),  ν(C=N)lumazine 1549 
(s);1H NMR (295 K/ppm): 11.68 (s, 1H, OH), 3.55 (s, 3H, C1-H3), 3.32 (d, 6H, N3-CH3, 








Figure 6.3: 1H NMR spectrum of ohlmz. Inset: The methyl signals of ohlmz. The non-integrated 
signals are associated with deuterated dimethylsulphoxide. 
 
6.2.2 Synthesis of metal complexes 
6.2.2.1  cis-[RuCl2(bzlmz)(PPh3)] (1) 
A mixture of bzlmz (0.0382 g; 0.104 mmol) and trans-[RuCl2(PPh3)3] (0.100 g; 0.104 
mmol) was dissolved in 20 cm3 of toluene. The resultant solution was heated until 
reflux for 6 hrs and filtered. Slow evaporation of the mother liquor gave dark brown 
crystals suitable for X-ray analysis. Yield = 68%; M.P. = 280 – 282 ˚C; IR (νmax/cm-1):  
ν(N-H)amide3374 (w), υ(C=O)lumazine 1710, 1692 (s),υ(C=O)amide 1623 (s), υ(C=N)lumazine 1534 
(s), ν(C-N)amide1268 (m), ν(Ru-PPh3) 695 (vs);1H NMR (295K/ppm): 10.97 (s, 1H, N6), 9.36 
(s, toluene), 8.16 (d, 2H, H14, H18), 7.66 – 7.06 (m, 18H, H15, H16, H17, PPh3), 3.60 (s, 3H, 
C8-H3), 2.73 (d, 6H, N1-CH3, N2-CH3), 2.11 (s, 3H, C11-H3); 31P NMR (295K/ppm): 25.55; 






nm (474); Conductivity (DCM, 10-3 M): 9.20 ohm-1cm-2mol-1; Anal. Calc. for 
C43H40Cl2N6O3PRu (%): C, 57.91; H, 4.52; N, 9.42. Found: C, 57.97; H, 4.18; N, 8.99;TOF-
MS (m/z): Calcd: 909.14 [M]; Found: 799.06 [M-H2O-C7H8].  
 
6.2.2.2  cis-[RuCl2(olmz)(PPh3)] (2) 
The title compound was formed from the 1:1 molar ratio reaction of ohlmz (0.0275 g; 
0.104 mmol) with trans-[RuCl2(PPh3)3] (0.100 g, 0.104 mmol) in 20 cm3 of toluene after 6 
hrs of heating at reflux temperature. A maroon precipitate was filtered and 
recrystallized from the slow diffusion of dichloromethane into n-hexane [1:1 (v:v)] 
which resulted in the formation of brown XRD quality crystals. Yield = 63%; M.P.> 350 
˚C; IR (νmax/cm-1): ν(C=O) 1688, 1620 (vs), ν(C=N) 1559 (m), ν(Ru-PPh3) 696 (s); UV-Vis 
(DCM, (λmax (ε, M-1cm-1))): 350 nm (6502); 461 nm (6646); 707 nm (550); Conductivity 
(DCM, 10-3M): 15.00 ohm-1cm-2mol-1; Anal. Calc. for C28H27Cl2N5O3PRu (%): C, 49.13; H, 
3.98; N, 10.23. Found: C, 49.05; H, 3.96; N, 9.91; TOF-MS (m/z): Calcd: 684.03 [M]; Found: 
684.02 [M].  
 
6.3 X-ray diffraction 
Crystal and structure refinement data are given in Table 6.2. Selected bond lengths and 
angles are given in Tables 6.3 and 6.4 for 1.C7H8.H2O and 2, respectively. In both cases, 
the data were collected with Mo Kα (λ = 0.71073 Å) radiation at a crystal-to-detector 
distance of 50 mm. The following conditions were used for data collection: omega and 
phi scans with exposures taken at 30 W X-ray power and 0.50º frame widths using 
APEX2 [17]. The data were reduced with the programme SAINT [17] using outlier 
rejection, scan speed scaling, as well as standard Lorentz and polarization correction 
factors. A SADABS semi-empirical multi-scan absorption correction [18] was applied to 






structures. All non-hydrogen atoms were located in the difference density map and 
refined anisotropically with SHELX-2014 [19]. All hydrogen atoms were included as 
idealised contributors in the least squares process. Their positions were calculated using 
a standard riding model with C-Haromatic distances of 0.93 Å and Uiso = 1.2 Ueq, C-Hmethylene 
distances of 0.99 Å and Uiso = 1.2 Ueq and C–Hmethyldistances of 0.98 Å and Uiso = 1.5 Ueq.  
The O-H bonds of water molecule for 1 were located in the difference density map and 
refined isotropically.  
 
6.4 Computational details 
Computational calculations were conducted with GAUSSIAN 09W [21]. Geometry 
optimization of the ruthenium complex 1 was achieved through a DFT calculation using 
the B3LYP functional, with an accompanying hybrid basis set viz. the 6-311G++ (d, p) 
basis set was applied to all the C, H, N, O, Cl and P atoms and the LANL2DZ basis set, 
which makes use of effective core potentials, applied to the metal centre [22]. Prior to 
the calculation, the solvent molecules of recrystallization for 1 were omitted from the 
crystal structure and the resultant structure was used as the starting conformer. Good 
agreement was found between the optimized and geometrical parameters (refer to 
Table 2) with the minor deviations attributed to the fact that gas phase optimized 
structure do not account for non-classical hydrogen bonding interactions or any short 
distance contacts. Using the optimized structure of the metal complex, the lack of any 
negative Eigen values in the frequency calculations confirmed that the structure is at a 
global minimum on the potential energy surface [23].  
 
6.5 Results and Discussion 
6.5.1 Synthesis, spectral characterization and computational studies 
The ruthenium(II) and –(III) complexes 1 and 2 were formulated from the 1:1 molar 






bzlmz and olmz, respectively. In 1 and 2, the bzlmz and ohlmz coordinates via their 
respective tridentate NiminoNpyrazineOketonicand OketonicNpyrazineOnitroso donor sets, (see section 
6.5.4, Figures6.15 and 6.18).  
 
Interestingly, a fascinating transformation is observed from the free-ligand, ohlmz to 
the olmz chelator, see Scheme 6.1. This instrinsic molecular transformation of ohlmz is 
inititiated by Beckmann rearrangement of the oxime ohlmz (refer to Step A) [24]. In step 
B, the resultant intermediate undergoes deacetylation which is accompanied by a 
reaction between the acetate group and acetic acid. In addition, ruthenium catalyzed 
demethylation of the diketonic aliphatic compound occurs [25]. Thereafter, the amido 
nitrogen undergoes ruthenium catalyzed oxidation to form a nitroso group, see Step C 
[26]. Subsequently, the nitroso oxygen is protonated and the methyl group bonds 
covalently to the aliphatic nitrogen, see Step D.  The compounds exhibit excellent 
solubility in alcoholic media and virtually all other polar solvents. The low conductivity 
values recorded for 1 and 2 confirm that both complexes are non-electrolytes in DCM. 
 
The IR spectra of bzlmz and its complex (Figure 6.4) show numerous vibrations 
between 1200 cm-1 to 1800 cm-1 which are poorly resolved due to the extended π-
conjugation within bzlmz. However, frequency calculations aided in the interpretation 
of these vibrations. More specifically, the simulated spectrum of 1 indicated a 
distinctive difference between coordinated ketonic and uncoordinated vibrations at 
1669 cm-1 and 1776 cm-1, respectively. In the overlay IR spectra of 1 and its free-ligand, 
an intense broad vibrational band at 1694 cm-1 (for the free-ligand, bzlmz) splits it into 
two vibrational bands at 1692 cm-1 (coordinated) and 1710 cm-1 (uncoordinated).  
 
The ν(C=O)amide is observed at 1740 cm-1 in the simulated spectrum of 1 while in the 
experimental spectra of 1 and its free-ligand, the amide C=O vibrations [1623 cm-1 for 1 






The simulated amide C-N (1265 cm-1) and C=N (1561 cm-1) compare well with the 
corresponding wavenumbers found for the peaks in the experimental spectra of 1 
[ν(C=N) at 1534 cm-1 and ν(C-N) at 1268 cm-1] and its free-ligand [ν(C=N) at 1547 cm-1 
and ν(C-N) at 1268 cm-1]. For 1, the N-H bond vibrates essentially at the same positions 
at 3374 and 3377 cm-1 in the experimental – and simulated IR spectra, respectively.  In 
both the experimental IR spectra of 1 and 2, an intense characteristic ruthenium to 














































































Figure 6.4: Overlay IR spectra of complex 1 and its free-ligand, bzlmz in the region of 380 to 
2000 cm-1. 
 







The 1H NMR spectrum of 1 is dominated by an intense multiplet attributed to the 
signals of the triphenylphosphine co-ligand and selected phenylic protons of the bzlmz 
chelator (see Figure 6.6). The remaining aromatic signal resonates as a doublet at 8.16 
ppm. The amide and methyl signals of the bzlmz chelator in 1 are found essentially at 
the same positions to analogous signals found within the proton spectrum of the 
corresponding free-ligand bzlmz. As expected, only one signal is observed in the 31P 













Figure 6.7: 31P NMR spectrum of complex 1. 
 
The UV-Vis spectra of the metal complexes show both intense π-π* intraligand 
transitions below 400 nm associated with the conjugated bzlmz (in 1) and olmz (in 2) 
chelators (see Figures 6.8 and 6.9). In the region (between 400 nm and 600 nm), 
distinctive charge transfer bands appears;  Metal-to-Ligand-Charge Transfer band at 
477 nm and Ligand-to-Metal-Charge Transfer band at 461 nm for 1 and 2, respectively. 
Despite complex 1 having a low-spin d6 electron configuration, it also has a metal-based 
d-d electronic transition such as observed for the paramagnetic complex 2 [677 nm for 1 
and 707 nm for 2]. The presence of the metal-based electronic transition of 1 is ascribed 
to a computed low band-gap energy (2.685 eV) which makes the d-d electronic 
transition favourable.  This finding concurs with our previous report where comparable 
band-gap energies were attained for the optimized structures of the ruthenium(II) 
complex cation,  [RuCl(Hobz)2(PPh3)]+ (Hobz = 2-hydroxyphenylbenzimidazole) [band-






[band-gap energy = 3.236 eV]; this computational data explained why both these 
metallic compounds had distinctive d-d electronic transitions [28]. 
 
Figure 6.8: Overlay UV-Vis spectra of complex 1 and its free-ligand, bzlmz. 
 






The EA data compare well with the calculated exact masses of the respective metal 
complexes while the low resolution mass spectra of 1 and 2 showed peaks 




Figure 6.10: Low resolution mass spectrum of complex 1. The mass spectrum indicates that 
the compound is highly ionisable which leads to an intricate fragmentation pattern. The [M-





Figure 6.11: Low resolution mass spectrum of complex 2. The mass spectrum indicates that 
the compound is highly ionisable which leads to an intricate fragmentation pattern. The [M]+ 






The EPR spectrum of 2 (see Figure 6.12) was obtained only in the solid state at room 
temperature. A low resolution singlet (g-value = 2.011) confirmed the presence of the 
paramagnetic metal centre of complex 2 in the solid state at 298 K.  The nature of the 
EPR spectrum of 2 is characteristic of some low spin ruthenium(III) octahedral 
complexes [29]. 
 
Figure 6.12: Solid state EPR spectrum of complex 2 at 298K. 
 
6.5.2 Electrochemistry studies 
The cyclic voltammograms (CVs) of 1 and 2 showed single redox couples attributed to 
the Ru(II)/Ru(III) redox couples as seen in Figure 6.13. The assignment is made based 
on the fact that their halfwave potentials [E½ = 0.96 V (for 1) and 0.83 V (for 2) vs 
Ag|AgCl] resides in the potential window of -0.15 V and 0.96 V for halfwave potentials 






the similar electrochemical conditions [28, 30]. In addition, these redox couples 
corresponds to one electron redox processes governed by their peak to peak seperations 
(Ipa/Ipc) approaching 1. Furthermore, the redox couples are quasi-reversible as the peak 
to peak seperations of 1 (ΔE = 80 mV) and 2 (ΔE = 70 mV) are smaller than that of the 
standard ferrocene (90 mV at 100 mV/s)indicating faster electron transfer kinetics for the 
metal complexes. Also, the two redox couples displayed diffusion controlled behaviour 
with increasing scan rates. For instance, Figure6.14 shows overlay CVs of complex 2 for 
scan rates ranging from 25 mV/s to 200 mV/s, at increments of 25 mV/s. 
 
 







Figure 6.14: Overlay CVs of complex 2 at incrementing scan ratesillustrating the diffusion-
controlled behaviour of its redox couple. 
 
6.5.3 Radical Scavenging studies 
The mutation of healthy cells by free radicals is reported to be a common cause of 
cancer, Alzheimer’s disease and cardiovascular diseases [31, 32]. To deter the negative 
effects of these free radicals, more effective radical scavengers are required other than 
the natural antioxidant, vitamin C. Previous studies have illustrated that ruthenium 
compounds have shown to be effective radical scavengers, largely owing to their 
optimal redox properties [33]. Indicative to these previous studies, the formulated 
ruthenium compounds 1 and 2 with lumazine moeities have shown to have 
significantly higher DPPH and NO radical scavenging activities in comparison to 
vitamin C [IC50(NO) = 210 µM and IC50(DPPH) = 147 µM], see Table 6.1 [34, 35, 36]. 
Furthermore, the metallic compounds have lower IC50 values than their corresponding 






In fact, the influence of the bzlmz chelator on the radical scavenging capability of 1 can 
be regarded as negligible. This deduction is based on the high IC50 values of the free-
ligand, bzlmz when used for the scavenging of the DPPH and NO radicals, respectively. 
In contrast to metal-centred radical scavenging activity of 1, the IC50 values of the free-
ligand, ohlmz suggested that there could be a synergetistic mechanistic effect of radical 
activity induced by the redox activity of the metal centre and the donation of hydrogen 
by the olmz chelator of (2). 
 
Table 6.1: IC50 values (in µM) of the metallic compounds and their free-ligands. Each IC50 value 







6.5.4 Crystallographic studies 
Complex 1 co-crystallize with a water and a toluene molecule of recrystallization (see 
Figure 6.15). Molecules of 1 affords chains parallel to the [a]-axis induced by hydrogen-
bonding between the water molecule and adjecent molecules of 1 (O4-HB····N3 = 
2.17(7) Å and O4-HA····Cl2 = 2.22(5) Å), see Figure 6.16. The crystal lattice of 1 is 
further stabilized by classical pi-pi interactions between the C19-C24 phenyl ring (of the 
triphenylphosphine co-ligand) and the C7C9N4C1C6N3 ring (of the bzlmz chelator) 
defined by the centroid to centroid distance of 3.371 Å. Intermolecular interactions are 
also observed between the nearly co-planar toluene molecule and  C6C1C2N1C4N2 
ring (of the bzlmz chelator) with an interplanar spacing of 3.770 Å, see Figure 6.17. The 
aforementioned intermolecular interactions induced the molecules of 1 to stack in 
 NO DPPH 
1 36 46 
2 34 63 
bzlmz 1002 392 






columns aligned with the [b]-axis. Complex 2 crystallize out in a C2/cspace-group with 
each monoclinic cell occupying 8 molecules of 2 (see Figure 6.18). Indicative to 1, 
complex 2 exhibits pi-stacking intramolecular interactions (at 3.480 Å) between the C11-
C16 phenyl ring (of the triphenylphosphine co-ligand) and N2C9C2N5C3C8 ring (of the 
bzlmz chelator), see Figure 6.19. 
 
The constrained five-membered chelate rings within 1 [N5-Ru-N4 = 77.48(9)˚ and N4-
Ru-O1 = 78.48(8)˚] and 2 [O1-Ru-N2 = 77.7(3)˚ and O2-Ru-N2 = 77.5(2)˚] afforded severe 
deviation in their respective octahedral given by the individual equotorial angles [N5-
Ru-O1 =155.86(8)˚, Cl1-Ru-N4 = 173.42(7)˚ for 1 and O1-Ru-O2 = 155.1(2)˚, N2-Ru-Cl1 = 
176.9(2)˚] all deviating from linearity. Furthermore, the lumazine moeity lies 
significantly out of the plane (by 87.32˚) of the C13-C18 phenyl ring which is accounts to 
the flexibility of the amide aliphatic group. The bond order of the C12-O3 [1.222(3) Å] 
bond is confirmed based on its similar distance in comparison to the ketonic C=O bonds 
within 1 [C2-O1 = 1.248(4) Å and C4-O2 =1.210(4) Å] and 2 [C7-O2 = 1.236(1) Å and C5-
O3 =1.21(1) Å]. The presence of the paramagnetic metal (for 2) is also confirmed based 
on the difference in the Ru-O [Ru-O1 = 1.993(8) Å and Ru-O2 = 2.335(5) Å] coordination 
bonds which affirms the olmz ligand acts as a tridentate monoanionic chelator. In fact, 
the ruthenium(III) complex, trans-[Ru(H2npbh)Cl(PPh3)2] (H2npbh = 2-hydroxy-1-
naphthaldehyde-benzoylhydrazone) had comparable Ru-Oketonic [1.9906(15) Å] and Ru-
Ophenolate [2.0382(14) Å] bond lengths as 1 [37]. The lower Lewis acidic character of the 
diamagnetic ruthenium atom (in 1) affords a shorter Ru-P [2.329(2) Å] coordination 
bond length in contrast to the analogous bond found within 2 [Ru-P = 2.329(2) Å]. 
However, despite the variable valency between 1 and 2, the ruthenium to lumazine 
nitrogen coordination bonds of both metal complexes are nearly equidistant [1.904(2) Å 
for 1 and 1.900(6) Å for 2]. In addition, the difference in the cis-orientated Ru-Cl bonds 






2.427(2) Å for 2]  within the respective complexes are accounted to the difference 
influence imposed on the halides.   
 
Although no ruthenium compounds (besides 1 and 2) bearing lumazine moeities can be 
found in the Cambridge Crystallographic Data Centre (CCDC), several transition metal 
complexes with lumazine chelates have been isolated [15, 38-41]. Among these 
transition metal complexes, the lumazine moeity and its multidentate chelators exhibits 
diverse coordination modes affording metal complexes with unique molecular 
geometries. In addition, several of these metal complexes exhibits unique anticancer 
activities while the presence of the lumazine moiety within the coordinates sphere of 
various d-block metals induces unique luminscent behaviours [39, 41]. 
 
Figure 6.15: An ORTEP view of compound 1 showing 50 % probability displacement ellipsoids 








Figure 6.16: A perspective view of the hydrogen-bonding occurring in 1;O4-HA····Cl2 = 
2.22(5) Å [A] and O4-HB····N3 = 2.17(7) Å [B]. 
 
Figure 6.17: A perspective view of inter- and intramolecular interactions stabilizing the crystal 









Figure 6.18: An ORTEP view of compound 2 showing 50 % probability displacement ellipsoids 



























Table 6.2: Crystal data and structure refinement data. 
 1·H2O·C7H8 2 
Chemical formula C43H42Cl2N6O4PRu C28H27Cl2N5O3PRu 
Formula weight 909.77 684.50 
Temperature (K) 100(2) 100(2) 
Crystal system Triclinic Monoclinic 
Space group P-1 C2/c 
Unit cell dimensions (Ǻ, °) a = 10.162(5)  a = 22.7645(13) 
 b = 13.587(5) b = 17.5745(11) 
  c = 16.268(5)  c = 17.3170(13) 
 α = 105.202(5) α = 90 
 β = 106.096(5) β = 110.728(3) 
 γ = 103.762(5) γ = 90 
Crystal size (mm) 0.19 × 0.18 × 0.12 mm 0.32 × 0.11 × 0.04 mm 
V(Å3)  1962.2 (13)  6479.6 (7) 
Z 2 8 
Density (calc.) (Mg/m3) 1.540  1.403 
Absorption coefficient (mm-1) 0.629 0.733 
F(000) 934 2776 
θ range for data collection (deg) 1.39; 26.05 1.50; 26.20 
Reflections measured 31830 23551 
Observed reflections [I>2σ(I)] 7117 5084 
Independent reflections 7653 6162 
Data/Restraints/parameters 7653/1/527 6162/0/365 
Goodness of fit on F2 1.085 1.047 
Observed R, wR2 0.0341; 0.0858 0.0792; 0.2074 






Table 6.3: Selected bond lengths [Å] and bond angles [°] for 1. 
 Experimental Optimized 
Ru-P 2.329(2) 2.4066 
Ru-N4 1.904(2) 1.9525 
Ru-N5 2.003(3) 2.0056 
Ru-Cl1 2.412(9) 2.4821 
Ru-Cl2 2.4527(9) 2.4481 
C12-O3 1.222(3) 1.2175 
C2-O1 1.248(4) 1.2357 
C4-O2 1.210(4) 1.2109 
N5-Ru-N4 77.48(9) 78.291 
N4-Ru-O1 78.48(8) 78.887 
N5-Ru-O1 155.86(8) 153.174 
Cl1-Ru-N4 173.42(7) 171.196 
 
 
Table 6.4: Selected bond lengths [Å] and bond angles [°] for 2. 
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Conclusion and Future Work 
 
Novel ruthenium complexes with multidentate N, X-donor (X = O, N, S) ligands 
encompassing various biologically relevant moieties were designed, synthesized and 
characterized. In addition, the optimal redox properties of these ruthenium 
complexes enable these metallic compounds to be radical scavengers. Furthermore, 
these multidentate chelators stabilized the metal centres in their respective oxidation 
states of +II, +III and +IV while conferring unique coordination modes. 
 
The isolation of ruthenium complexes with Schiff base chelates containing 
benz(imidazole/othiazole/oxazole) moieties are described in chapter 3. Despite the 
structural similarities of the ligands, ruthenium(II) and -(III) complexes with unique 
structural features were obtained. The voltammetric assignments of the formulated 
metallic complexes were corroborated by UV-Vis spectroelectrochemistry 
experiments. ESR studies of the paramagnetic metal complexes confirmed their 
rhombic nature.  
 
Chapter 4 reports the formation of ruthenium compounds bearing N-X donor (X = 
O, N) heterocyclic chelators. These chelators include benzoxazole-amide, 
benzimidazole-amines and chromone-derived Schiff base ligands. X-ray analysis 
revealed that the metal atoms in the mononuclear ([RuCl(pho)(bzca)(PPh3)] (1) and 
cis-Cl, trans-P-[RuIII(Hbhb)Cl2(PPh3)2] (2)) and dinuclear ((μ-Htba,Cl)2[RuIICl(PPh3)]2 
(3) and (µ-Cl)2[RuIIICl(Hchpr)(PPh3)]2 (4)) metallic compounds are within centres of 
distorted octahedrons which are largely induced by the influence of chelating co-






hydrogen bonding supported by weak intermolecular bonding which results in 
diverse supramolecular structures. A proposed formation route of compound 1 
supported by the literature provided insight into the unique molecular 
transformation of Hbzap into the pho and bzca bidentate chelators. Furthermore, the 
redox properties of these metallic compounds are comparable to other ruthenium 
compounds found within the literature. In addition, the metallic compounds had 
significantly higher radical scavenging capabilities than their corresponding free-
ligands and the natural antioxidant, Vitamin C. 
 
In chapter 5, the coordination behaviours of the diimines (viz. 2,6-bis-((4-
tetrahydropyranimino)methyl)pyridine(thppy) and N1,N2-bis((3-
chromone)methylene)benzene-1,2-diamine(chb)) and the triimine (viz.tris-((1H-
pyrrol-2-ylmethylene)ethane)amine (H3pym)) towards the trans-[Ru(PPh3)2]2+ core 
afforded novel coordination compounds with diverse structural features: cis-
[RuCl2(thppy)(PPh3)] (1), (µ-chb)[mer-RuCl3(PPh3)]2 (2) and [Ru(pym)] (3). The thppy 
chelator of 1 acts as a neutral tridentate ligand through its (NN)iminoNpy donor set 
while the neutral chb ligand of 2 bridges the two cis-[RuIIICl3] cores via its ketonic 
oxygen and imino nitrogen atoms. In addition, the triimine ligand pym displaces all 
of the co-ligands of the metal precursor affording the hexa-coordinate tris(pyrrolide-
imine) chelate of Ru(III), complex 3. All the metal complexes have lower IC50 values 
in comparison to their corresponding free ligands while predominately all metallic 
compounds were more effective scavengers than the natural antioxidant, vitamin C. 
 
Chapter 6 presents the formulation and spectroscopic characterization of ruthenium 
complexes with scaffolds incorporating lumazine moieties. Computational 
calculations at the DFT level aided in the interpretation of the experimental spectra 
of the metal complexes. X-ray analysis affirms the structural elucidation indicating 
that the metal atoms are in the centres of distorted octahedrons which are induced 






The abovementioned results provide scope for investigating the anticancer, 
antimicrobial and antimalarial activities of the formulated metallic compounds.  
However, before the anticancer studies will be conducted, we envisage exploring the 
interactions of these metal complexes towards Calf Thymus (CT)-DNA and 
confirming the mode of interactions using Gel Electrophoresis. The aforementioned 
experiments are motivated by the fact that recent studies have shown that 
ruthenium(II) complexes with bulky triphenylphosphine co-ligands exhibit optimal 
DNA binding and protein interaction capabilities which was accompanied with 
lower cell toxicity [1]. Furthermore, there is an upsurge in the radiochemistry of 
ruthenium for development of new therapeutic ruthenium radiopharmaceuticals 
ascribed to the optimal half-life (371.8 days) and β-max energy of the 106-ruthenium 
radionuclide [2].  
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